FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Simons, RE
   Zevy, DL
   Jafferany, M
AF Simons, Robert E.
   Zevy, Danna L.
   Jafferany, Mohammad
TI Psychodermatology of vitiligo: Psychological impact and consequences
SO DERMATOLOGIC THERAPY
LA English
DT Review; Early Access
DE psychocutaneous disorders; psychodermatology; psychological; vitiligo
ID QUALITY-OF-LIFE; MORBIDITY
AB Vitiligo is an autoimmune dermatologic disorder that causes chronic skin depigmentation, which affects an estimated 1% of the world's population. This disfiguring condition can have devastating psychological consequences on its sufferers. The field of psychodermatology examines psychiatric manifestations of dermatologic conditions. Although previous research in this area has been done on other skin disorders, no large-scale review exists on the dermatologic-psychiatric connection in vitiligo specifically. The current article will discuss the psychodermatology of vitiligo with an emphasis on depression, stress, and low self-esteem. The social and cultural considerations will also be explored. Finally, the implications of these psychiatric manifestations on treatment will be discussed, with the goal of implementing early psychiatric intervention for those with vitiligo.
C1 [Simons, Robert E.; Zevy, Danna L.; Jafferany, Mohammad] Cent Michigan Univ, Dept Psychiat, Coll Med, Saginaw, MI 48602 USA.
RP Jafferany, M (corresponding author), Cent Michigan Univ, Dept Psychiat, Coll Med, Saginaw, MI 48602 USA.
EM mjafferany@yahoo.com
OI Jafferany, Mohammad/0000-0001-6358-9068
CR Bonotis K, 2016, J DTSCH DERMATOL GES, V14, P45, DOI 10.1111/ddg.12729
   Gurpinar A, 2019, TURK J MED SCI, V49, P832, DOI 10.3906/sag-1812-84
   Ongenae K, 2006, J EUR ACAD DERMATOL, V20, P1, DOI 10.1111/j.1468-3083.2005.01369.x
   Osinubi O, 2018, BRIT J DERMATOL, V178, P863, DOI 10.1111/bjd.16049
   Parsad Davinder, 2003, Health Qual Life Outcomes, V1, P58, DOI 10.1186/1477-7525-1-58
   Sangma LN, 2015, INDIAN J DERMATOL, V60, P142, DOI 10.4103/0019-5154.152508
   Sarkar S, 2018, INDIAN J DERMATOL, V63, P281, DOI 10.4103/ijd.IJD_142_18
   Schmid-Ott G, 2007, J EUR ACAD DERMATOL, V21, P456, DOI 10.1111/j.1468-3083.2006.01897.x
   Silvan M, 2004, CUTIS, V73, P163
   Silverberg JI, 2015, CUTIS, V95, P255
NR 10
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e13418
DI 10.1111/dth.13418
EA MAY 2020
PG 4
WC Dermatology
SC Dermatology
GA LJ8WV
UT WOS:000530442900001
PM 32297399
DA 2020-07-08
ER

PT J
AU Lacerda, KAP
   Silva, LA
   Mendonca, GS
   Guimaraes, RA
   Guild, LA
AF Pereira Lacerda, Kenia Alves
   Silva, Luiz Almeida
   Mendonca, Guilherme Silva
   Guimaraes, Rafael Alves
   Guild, Lidia Andreu
TI ASSOCIATION BETWEEN QUALITY OF LIFE AND PERCEIVED STRESS IN PATIENTS
   WITH VITILIGO: CASE CONTROL STUDY
SO BIOSCIENCE JOURNAL
LA English
DT Article
DE Skin; Perceived Stress; Quality of life
ID INDEX SCORE; IMPACT; EPIDEMIOLOGY; EVENTS
AB To evaluate the association between quality of life (QL), perceived stress in patients with vitiligo and compare the perception of stress with noncarriers. The first study was cross-secctional, and the second case-control with 51 patients in outpatient treatment and 51 users of a blood center, matched by sex and age. Questionnaires used were Dermatology Life Quality Index and Perceived Stress Scale. Results: The mean score of quality of life in patients was 4.7 +/- 5.8, showing a slight impairment in QL. There was association between QL and black skin color (p <0.001), involvement of standard exposed vitiligo (p < 0.001) and perceived stress (p = 0.033). The perceived stress rated among the groups showed an average of 20.7 +/- 6.0 and 17.8 +/- 7.0 for cases and controls, respectively. Vitiligo patients had higher perceived stress compared to the control group (p = 0.022). The results showed a high perceived stress in patients with vitiligo, suggesting that the disease increases the level of stress. The overall score of the quality of life was relatively low indicating mild impairment of disease on quality of life.
C1 [Pereira Lacerda, Kenia Alves] Fed Inst Educ Sci & Technol Goias, Campus Jatai, Jatai, Go, Brazil.
   [Silva, Luiz Almeida] Fed Univ Catalao, Biotechnol Acad Unit, Catalao, Go, Brazil.
   [Mendonca, Guilherme Silva] Univ Fed Uberlandia, Hlth Sci, Uberlandia, MG, Brazil.
   [Mendonca, Guilherme Silva] Univ Fed Uberlandia, Hosp Clin, Uberlandia, MG, Brazil.
   [Guimaraes, Rafael Alves] Goias Fed Univ, Grad Program Trop Med, Goiania, Go, Brazil.
   [Guild, Lidia Andreu] Goias Fed Univ, Inst Biol Sci, Campus 2 Lab Cell Biochem, Goiania, Go, Brazil.
RP Lacerda, KAP (corresponding author), Fed Inst Educ Sci & Technol Goias, Campus Jatai, Jatai, Go, Brazil.
EM kenialacerdaalves@gmail.com
OI Silva, Luiz Almeida/0000-0002-6661-035X
CR Ahmed S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148211
   Alikhan A, 2011, J AM ACAD DERMATOL, V65, P473, DOI 10.1016/j.jaad.2010.11.061
   Amer AAA, 2016, INT J DERMATOL, V55, P608, DOI 10.1111/ijd.13198
   BATISTA K. M., 2011, THESIS
   Both H, 2007, J INVEST DERMATOL, V127, P2726, DOI 10.1038/sj.jid.5701142
   Chan MF, 2013, INT J NURS PRACT, V19, P3, DOI 10.1111/ijn.12179
   Dolatshahi M, 2008, INDIAN J DERMATOL VE, V74
   Ghajarzadeh Mahsa, 2012, Acta Med Iran, V50, P511
   Hongbo Y, 2005, J INVEST DERMATOL, V125, P659, DOI 10.1111/j.0022-202X.2005.23621.x
   Ingordo V, 2012, GIORN ITAL DERMAT V, V147, P83
   Kiprono S, 2013, INT J DERMATOL, V52, P191, DOI 10.1111/j.1365-4632.2012.05600.x
   Kostopoulou P, 2009, BRIT J DERMATOL, V161, P128, DOI 10.1111/j.1365-2133.2009.09077.x
   Manolache L, 2007, J EUR ACAD DERMATOL, V21, P921, DOI 10.1111/j.1468-3083.2006.02106.x
   Martins Gladys Aires, 2004, An. Bras. Dermatol., V79, P521, DOI 10.1590/S0365-05962004000500002
   Mashayekhi V, 2010, INDIAN J DERMATOL VE, V76, DOI 10.4103/0378-6323.69097
   Mechri Anwar, 2006, Tunis Med, V84, P632
   MERLI A., 2014, ARCH ARGENT DERMATOL, V64, P139
   Ongenae K, 2005, BRIT J DERMATOL, V152, P1165, DOI 10.1111/j.1365-2133.2005.06456.x
   Ongenae K, 2005, DERMATOLOGY, V210, P279, DOI 10.1159/000084751
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Parsad D, 2003, BRIT J DERMATOL, V148, P373, DOI 10.1046/j.1365-2133.2003.05097_9.x
   Picardi A, 2003, PSYCHOTHER PSYCHOSOM, V72, P150, DOI 10.1159/000069731
   Radtke MA, 2009, BRIT J DERMATOL, V161, P134, DOI 10.1111/j.1365-2133.2009.09091.x
   Razali NM, 2011, J STAT MODELL ANAL, V2, P21, DOI DOI 10.1515/BILE-2015-0008
   Reis RS, 2010, J HEALTH PSYCHOL, V15, P107, DOI 10.1177/1359105309346343
   Shah M, 2006, BRIT J DERMATOL, V154, P150, DOI 10.1111/j.1365-2133.2005.06959.x
   Silverberg JI, 2013, JAMA DERMATOL, V149, P159, DOI 10.1001/jamadermatol.2013.927
   Silverberg NB, 2015, CURR DERMATOL REP, V4, P36, DOI 10.1007/s13671-014-0098-6
   Taborda Maria-Laura V. V., 2005, An. Bras. Dermatol., V80, P351, DOI 10.1590/S0365-05962005000400004
   Tanioka M, 2010, J COSMET DERMATOL-US, V9, P72, DOI 10.1111/j.1473-2165.2010.00479.x
   Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd
   Wang KY, 2011, J EUR ACAD DERMATOL, V25, P429, DOI 10.1111/j.1468-3083.2010.03808.x
   WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
   Wong SM, 2012, INT J DERMATOL, V51, P158, DOI 10.1111/j.1365-4632.2011.04932.x
   Zhang YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163806
NR 35
TC 0
Z9 0
U1 0
U2 0
PU UNIV FEDERAL UBERLANDIA
PI UBERLANDIA
PA AV PARA, 1720 CAMPUS UMUARAMA, UBERLANDIA, 38400-902, BRAZIL
SN 1981-3163
J9 BIOSCI J
JI Biosci. J.
PD MAY-JUN
PY 2020
VL 36
IS 3
BP 1032
EP 1042
DI 10.14393/BJ-v36n3a2020-45105
PG 11
WC Agriculture, Multidisciplinary; Agronomy; Biology
SC Agriculture; Life Sciences & Biomedicine - Other Topics
GA LH8TU
UT WOS:000529057300035
OA Bronze
DA 2020-07-08
ER

PT J
AU Yan, SL
   Shi, JP
   Sun, DJ
   Lyu, LC
AF Yan, Shili
   Shi, Jingpei
   Sun, Dongjie
   Lyu, Lechun
TI Current insight into the roles of microRNA in vitiligo
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Review
DE Vitiligo; microRNA; Melanocyte; Melanin; Polymorphism
ID OXIDATIVE STRESS; ENERGY-METABOLISM; PERIPHERAL-BLOOD; EXPRESSION;
   ASSOCIATION; MIRNA; POLYMORPHISM; TARGETS; SUSCEPTIBILITY; MELANOCYTES
AB Vitiligo is a common chronic depigmented skin disease characterized by melanocyte loss or dysfunction in the lesion. The pathogenesis of vitiligo has not been fully clarified. Most studies have suggested that the occurrence and progression of vitiligo are due to multiple factors and gene interactions in which noncoding RNAs contribute to an individual's susceptibility to vitiligo. Noncoding RNAs, including microRNAs (miRNAs), are a hot topic in posttranscriptional regulatory mechanism research. miRNAs are noncoding RNAs with a length of approximately 22 nucleotides and play a negative regulatory role by binding to the 3 '-UTR or 5 '-UTR of the target mRNA to inhibit translation or initiate mRNA degradation. Previous studies have screened the differential expression profiles of miRNAs in the skin lesions, melanocytes, peripheral blood mononuclear cells (PBMCs) and sera of patients and mouse models with vitiligo. Moreover, several studies have focused on miRNA-25, miRNA-155 and other miRNAs involved in melanin metabolism, oxidative stress, and melanocyte proliferation and apoptosis. These miRNAs and regulatory processes further illuminate the pathogenesis of vitiligo and provide hope for the application of small molecules in the treatment of vitiligo. In this review, we summarize miRNA expression profiles in different tissues of vitiligo patients and the mechanisms by which key miRNAs mediate vitiligo development.
C1 [Yan, Shili; Shi, Jingpei; Lyu, Lechun] Kunming Med Univ, Sci & Technol Achievement Incubat Ctr, 1168 West Chunrong Rd,Yuhua Ave, Kunming 650500, Yunnan, Peoples R China.
   [Yan, Shili; Sun, Dongjie] Kunming Med Univ, Affiliated Hosp 1, Dept Dermatol, Kunming, Yunnan, Peoples R China.
   [Shi, Jingpei] Kunming Med Univ, Sch Basic Med Sci, Kunming, Yunnan, Peoples R China.
RP Lyu, LC (corresponding author), Kunming Med Univ, Sci & Technol Achievement Incubat Ctr, 1168 West Chunrong Rd,Yuhua Ave, Kunming 650500, Yunnan, Peoples R China.
EM minimillet@hotmail.com
RI Lyu, Lechun/AAM-4839-2020
OI Lyu, Lechun/0000-0003-0095-4050
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [81560502, 81960354]; National Natural
   Science Foundation of Yunnan Province [2017FB116]; Talent Project of
   Yunnan Province [2019HB024]; 100 Talents Program of Kunming Medical
   University
FX Supported by grants from the National Natural Science Foundation of
   China (NSFC; Grant Nos. 81560502, 81960354), the National Natural
   Science Foundation of Yunnan Province (Grant No. 2017FB116), the Talent
   Project of Yunnan Province (2019HB024), 100 Talents Program of Kunming
   Medical University (Lechun Lyu). The authors acknowledge the editors and
   reviewers for their positive and constructive comments and suggestions
   on our study.
CR Ahangari F, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0173-7
   Alivernini S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01932
   Boniface K, 2016, GIORN ITAL DERMAT V, V151, P44
   Bordignon M, 2013, J DERMATOL SCI, V71, P142, DOI 10.1016/j.jdermsci.2013.04.005
   Cai Yimei, 2009, Genomics Proteomics & Bioinformatics, V7, P147, DOI 10.1016/S1672-0229(08)60044-3
   Cui TT, 2015, ARCH DERMATOL RES, V307, P683, DOI 10.1007/s00403-015-1563-1
   Dai XD, 2015, PIGM CELL MELANOMA R, V28, P217, DOI 10.1111/pcmr.12334
   Delmas V, 2019, EXP DERMATOL, V28, P662, DOI 10.1111/exd.13858
   El-Lithy GM, 2016, TRANSL RES, V177, P85, DOI 10.1016/j.trsl.2016.06.005
   Ezzedine K, 2016, JAMA-J AM MED ASSOC, V316, P1708, DOI 10.1001/jama.2016.12399
   Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7
   Faria AR, 2017, PATHOL RES PRACT, V213, P199, DOI 10.1016/j.prp.2016.12.019
   Grijalvo S, 2018, GENES-BASEL, V9, DOI 10.3390/genes9020074
   Gu JY, 2017, BIOMED PHARMACOTHER, V93, P969, DOI 10.1016/j.biopha.2017.07.010
   He YM, 2017, SCI REP-UK, V7, DOI 10.1038/srep42394
   Huang Y, 2012, SINGLE NUCLEOTIDE PO
   Huang Y, 2013, PIGM CELL MELANOMA R, V26, P338, DOI 10.1111/pcmr.12081
   Jacquemin C, 2019, PIGM CELL MELANOMA R, V32, P588, DOI 10.1111/pcmr.12763
   Jadeja SD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180958
   Jia WR, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000009846, 10.1097/md.0000000000009846]
   Lee AY, 2012, ANN DERMATOL, V24, P115, DOI 10.5021/ad.2012.24.2.115
   Lee I, 2009, GENOME RES, V19, P1175, DOI 10.1101/gr.089367.108
   Li YS, 2019, BRIEF BIOINFORM, V20, P1193, DOI 10.1093/bib/bbx137
   Lu LC, 2014, GENE, V535, P12, DOI 10.1016/j.gene.2013.11.024
   Lv MF, 2019, MOL MED REP, V20, P3617, DOI 10.3892/mmr.2019.10607
   Majid Imran, 2015, Indian J Dermatol Venereol Leprol, V81, P600, DOI 10.4103/0378-6323.168325
   Mansuri MS, 2017, BRIT J DERMATOL, V177, P1590, DOI 10.1111/bjd.15681
   Mansuri MS, 2014, BRIT J DERMATOL, V171, P1263, DOI 10.1111/bjd.13109
   Mazar J, 2016, MOL CELL BIOL, V36, P1090, DOI 10.1128/MCB.00762-15
   Mione M, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12346
   Mohan GC, 2015, JAMA DERMATOL, V151, P522, DOI 10.1001/jamadermatol.2014.3324
   Qiu L, 2014, J INVEST DERMATOL, V134, P2074, DOI 10.1038/jid.2014.241
   Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811
   Sahmatova L, 2016, ACTA DERM-VENEREOL, V96, P742, DOI 10.2340/00015555-2394
   Sahoo A, 2019, J INVEST DERMATOL, V139, P167, DOI 10.1016/j.jid.2018.06.189
   Sahoo A, 2017, J INVEST DERMATOL, V137, P1965, DOI 10.1016/j.jid.2017.04.025
   Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746
   Shang Z, 2017, STUDY BIOL EFFECTS M
   Shang ZW, 2017, J DERMATOL, V44, P1138, DOI 10.1111/1346-8138.13886
   Shi Q, 2016, CELL DEATH DIFFER, V23, P496, DOI 10.1038/cdd.2015.117
   Shi YL, 2014, EXP DERMATOL, V23, P140, DOI 10.1111/exd.12319
   Shi YL, 2013, PIGM CELL MELANOMA R, V26, P418, DOI 10.1111/pcmr.12086
   Singh RK, 2016, AUTOIMMUN REV, V15, P397, DOI 10.1016/j.autrev.2016.01.004
   Speeckaert R, 2017, AUTOIMMUN REV, V16, P937, DOI 10.1016/j.autrev.2017.07.005
   Speeckaert R, 2017, AM J CLIN DERMATOL, V18, P733, DOI 10.1007/s40257-017-0298-5
   Spiegelman VS, 2017, J INVEST DERMATOL, V137, P1828, DOI 10.1016/j.jid.2017.06.012
   Su MY, 2019, EXP CELL RES, V384, DOI 10.1016/j.yexcr.2019.111615
   Vaish U, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46529-6
   Wang Y, 2016, IMMUNOBIOLOGY, V221, P1378, DOI 10.1016/j.imbio.2016.07.008
   Wang Y, 2015, J DERMATOL, V42, P193, DOI 10.1111/1346-8138.12725
   Zhang Y, 2011, MECH RES MIR 423 5P
NR 51
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD APR
PY 2020
VL 47
IS 4
BP 3211
EP 3219
DI 10.1007/s11033-020-05336-3
EA FEB 2020
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LE1CZ
UT WOS:000516341400002
PM 32086720
DA 2020-07-08
ER

PT J
AU Henning, SW
   Jaishankar, D
   Barse, LW
   Dellacecca, ER
   Lancki, N
   Webb, K
   Janusek, L
   Mathews, HL
   Price, RN
   Le Poole, IC
AF Henning, Steven W.
   Jaishankar, Dinesh
   Barse, Levi W.
   Dellacecca, Emilia R.
   Lancki, Nicola
   Webb, Kirsten
   Janusek, Linda
   Mathews, Herbert L.
   Price, Ronald N., Jr.
   Le Poole, I. Caroline
TI The relationship between stress and vitiligo: Evaluating perceived
   stress and electronic medical record data
SO PLOS ONE
LA English
DT Article
ID PSYCHOLOGICAL STRESS; METABOLIC SYNDROME; OXIDATIVE STRESS;
   AUTOIMMUNE-DISEASES; IMMUNE FUNCTION; ASSOCIATION; DYSFUNCTION;
   PREVALENCE; DEPRESSION; ADULTS
AB Vitiligo is a T-cell mediated skin disorder characterized by progressive loss of skin color. In individuals genetically predisposed to the disease, various triggers contribute to the initiation of vitiligo. Precipitating factors can stress the skin, leading to T-cell activation and recruitment. Though hereditary factors are implicated in the pathogenesis of vitiligo, it is unknown whether precipitating, stressful events play a role in vitiligo. To understand this, we utilized a validated perceived stress scale (PSS) to measure this parameter in vitiligo patients compared to persons without vitiligo. Additionally, we probed a clinical database, using a knowledge linking software called ROCKET, to gauge stress-related conditions in the vitiligo patient population. From a pool of patients in an existing database, a hundred individuals with vitiligo and twenty-five age- and sex-matched comparison group of individuals without vitiligo completed an online survey to quantify their levels of perceived stress. In parallel, patients described specifics of their disease condition, including the affected body sites, the extent, duration and activity of their vitiligo. Perceived stress was significantly higher among vitiligo individuals compared to those without vitiligo. ROCKET analyses suggested signs of metabolic-related disease (i.e., 'stress') preceding vitiligo development. No correlation was found between perceived stress and the stage or the extent of disease, suggesting that elevated stress may not be a consequence of pigment loss alone. The data provide further support for stress as a precipitating factor in vitiligo development.
C1 [Henning, Steven W.; Barse, Levi W.] Loyola Univ Chicago, Oncol Res Inst, Maywood, IL USA.
   [Jaishankar, Dinesh; Dellacecca, Emilia R.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA.
   [Lancki, Nicola; Le Poole, I. Caroline] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA.
   [Webb, Kirsten] Loyola Univ Chicago, Div Dermatol, Maywood, IL USA.
   [Janusek, Linda] Loyola Univ Chicago, Marcella Niehoff Sch Nursing, Maywood, IL USA.
   [Mathews, Herbert L.] Loyola Univ Chicago, Dept Microbiol & Immunol, Maywood, IL USA.
   [Price, Ronald N., Jr.] Loyola Univ Chicago, Off Informat & Syst Dev, Maywood, IL USA.
   [Le Poole, I. Caroline] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL USA.
RP Jaishankar, D (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA.
EM dinesh.jaishankar@northwestern.edu
OI Le Poole, I. Caroline/0000-0001-6853-4007; Dellacecca,
   Emilia/0000-0001-9031-2240
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA191317]
FX CLP, R01CA191317, National Cancer Institute; https://www.cancer.gov/The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Harbi Mana, 2013, Skinmed, V11, P327
   Al-Shobaili HA, 2011, INT J HEALTH SCI-IJH, V5, P167
   ALABADIE MSK, 1994, BRIT J DERMATOL, V131, P160
   ALBERT DM, 1979, OPHTHALMOLOGY, V86, P1145
   Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x
   Amer AAA, 2016, INT J DERMATOL, V55, P608, DOI 10.1111/ijd.13198
   Asea A, 2007, J BIOSCIENCES, V32, P579, DOI 10.1007/s12038-007-0057-5
   Atas H, 2017, BALK MED J, V34, P219, DOI 10.4274/balkanmedj.2016.1005
   Baldini E, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00290
   Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284
   Carella AM, 2010, CURR DIABETES REV, V6, P215, DOI 10.2174/157339910791658844
   Cedercreutz K, 2010, J DERMAT NURSES ASSO, V2, P265, DOI 10.1097/JDN.0b013e3181fe9b33
   Chandola T, 2006, BMJ-BRIT MED J, V332, P521, DOI 10.1136/bmj.38693.435301.80
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Cohen S, 2012, J APPL SOC PSYCHOL, V42, P1320, DOI 10.1111/j.1559-1816.2012.00900.x
   COHEN Y, 1988, J CHEM SOC PERK T 2, P31, DOI 10.1039/p29880000031
   Cupertino F, 2017, CLIN DERMATOL, V35, P292, DOI 10.1016/j.clindermatol.2017.01.001
   Dell'Anna ML, 2010, J CELL PHYSIOL, V223, P187, DOI 10.1002/jcp.22027
   Dhabhar FS, 2014, IMMUNOL RES, V58, P193, DOI 10.1007/s12026-014-8517-0
   Dhabhar FS, 2009, NEUROIMMUNOMODULAT, V16, P300, DOI 10.1159/000216188
   El-Sayed MIK, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00197
   Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x
   Ezzedine K, 2012, PIGM CELL MELANOMA R, V25, pE1, DOI 10.1111/j.1755-148X.2012.00997.x
   Garvey WT, 2006, HDB CLIN NUTR, P357
   Gill L, 2016, J AM ACAD DERMATOL, V74, P295, DOI 10.1016/j.jaad.2015.08.063
   Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571
   He YM, 2017, SCI REP-UK, V7, DOI 10.1038/srep42394
   HOWITZ J, 1977, ARCH DERMATOL, V113, P47, DOI 10.1001/archderm.113.1.47
   Jin Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08337-4
   Kammerer R, 2002, J IMMUNOL, V168, P108, DOI 10.4049/jimmunol.168.1.108
   Karsli N, 2014, J INT MED RES, V42, P799, DOI 10.1177/0300060513516294
   Kruger C, 2015, ACTA DERM-VENEREOL, V95, P553, DOI 10.2340/00015555-1981
   Kruger C, 2012, INT J DERMATOL, V51, P1206, DOI 10.1111/j.1365-4632.2011.05377.x
   Lacetera N., 2016, INNATE IMMUNE RESPON, P107
   Lazzeri L, 2016, BIOMED RES INT, V2016, P5, DOI [10.3389/fgene.2016.00003, DOI 10.3389/FGENE.2016.00003]
   Le Poole IC, 2004, J INVEST DERM SYMP P, V9, P68, DOI 10.1111/j.1087-0024.2004.00825.x
   Le Poole IC, 2001, PIGM CELL RES, V14, P475, DOI 10.1034/j.1600-0749.2001.140608.x
   Liana Manolache D P-S, 2013, WORLD J DERMATOL, V2, P16
   Manolache L, 2007, J EUR ACAD DERMATOL, V21, P921, DOI 10.1111/j.1468-3083.2006.02106.x
   Mason CP, 2005, CLIN EXP DERMATOL, V30, P344, DOI 10.1111/j.1365-2230.2005.01779.x
   Mastore M, 2005, FEBS J, V272, P2407, DOI 10.1111/j.1742-4658.2005.04661.x
   Mohamed ES, 2017, EGYPT J OTOLARYNGOL, V33, P594, DOI 10.4103/ejo.ejo_6_17
   Mosenson JA, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12208
   Mosenson JA, 2012, PIGM CELL MELANOMA R, V25, P88, DOI 10.1111/j.1755-148X.2011.00916.x
   Nagarajan A, 2015, INDIAN J DERMATOL, V60, DOI 10.4103/0019-5154.147844
   Nicolaidou E, 2012, J AM ACAD DERMATOL, V66, P954, DOI 10.1016/j.jaad.2011.07.010
   Onder G, 2005, J GERONTOL A-BIOL, V60, P1168, DOI 10.1093/gerona/60.9.1168
   Ott C, 2009, CURR HYPERTENS REP, V11, P143, DOI 10.1007/s11906-009-0025-6
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Parsad Davinder, 2003, Health Qual Life Outcomes, V1, P58, DOI 10.1186/1477-7525-1-58
   Peng QL, 2020, CLIN EXP IMMUNOL, V199, P314, DOI 10.1111/cei.13404
   Phillips A. C, 2013, ENCY BEHAV MED, P1453
   Picardo M, 2015, J INVEST DERMATOL, V135, P1713, DOI 10.1038/jid.2015.92
   Pietrzak A, 2012, DERMATOL THER, V25, pS41, DOI 10.1111/dth.12012
   Pizzagalli DA, 2007, BEHAV RES THER, V45, P2742, DOI 10.1016/j.brat.2007.07.013
   Plantinga L, 2017, LUPUS, V26, P1064, DOI 10.1177/0961203317693095
   Pyykko nen AJ, 2009, BOT STUDY, P1935
   Ryu H, 2018, NAT IMMUNOL, V19, P583, DOI 10.1038/s41590-018-0102-6
   SALZER BA, 1995, DERMATOLOGY, V190, P109, DOI 10.1159/000246657
   Sangma LN, 2015, INDIAN J DERMATOL, V60, P142, DOI 10.4103/0019-5154.152508
   Shen CB, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00003
   Silverberg JI, 2015, CUTIS, V95, P255
   Slangier U, 2003, PSYCHOL ASSESSMENT, V15, P532, DOI 10.1037/1040-3590.15.4.532
   Small HY, 2018, FREE RADICAL BIO MED, V125, P104, DOI 10.1016/j.freeradbiomed.2018.05.085
   Stojanovich L, 2008, AUTOIMMUN REV, V7, P209, DOI 10.1016/j.autrev.2007.11.007
   Tamashiro KL, 2011, STRESS, V14, P468, DOI 10.3109/10253890.2011.606341
   Thompson AR, 2002, BRIT J HEALTH PSYCH, V7, P213, DOI 10.1348/135910702169457
   Treharne GJ, 2007, BRIT J HEALTH PSYCH, V12, P323, DOI 10.1348/135910706X109288
   Wei CL, 2008, INT J HEMATOL, V88, P52, DOI 10.1007/s12185-008-0105-4
   Wolf VL, 2019, CURR HYPERTENS REP, V21, DOI 10.1007/s11906-019-0914-2
   Yamaguchi Y, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017046
   Yang LF, 2015, CURR NEUROPHARMACOL, V13, P494, DOI 10.2174/1570159X1304150831150507
   Yang RL, 2008, J CLIN BIOCHEM NUTR, V43, P154, DOI 10.3164/jcbn.2008044
   Yildirim M, 2003, J DERMATOL, V30, P104, DOI 10.1111/j.1346-8138.2003.tb00356.x
   Zhang YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163806
NR 75
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2020
VL 15
IS 1
AR e0227909
DI 10.1371/journal.pone.0227909
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP8YP
UT WOS:000534603400032
PM 31986193
OA DOAJ Gold, Green Published
DA 2020-07-08
ER

PT J
AU Bastonini, E
   Kovacs, D
   Iacovelli, P
   Pacifico, A
   Picardo, M
AF Bastonini, E.
   Kovacs, D.
   Iacovelli, P.
   Pacifico, A.
   Picardo, M.
TI Autophagy is an adaptive stress response in Vitiligo
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 49th Annual Meeting of the European-Society-for-Dermatological-Research
   (ESDR)
CY SEP 18-21, 2019
CL Bordeaux, FRANCE
SP European Soc Dermatol Res
C1 [Bastonini, E.; Kovacs, D.; Iacovelli, P.; Pacifico, A.; Picardo, M.] IRCCS, San Gallicano Dermatol Inst, Rome, Italy.
OI Iacovelli, Paolo/0000-0001-8711-4868
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD SEP
PY 2019
VL 139
IS 9
SU S
MA 526
BP S305
EP S305
DI 10.1016/j.jid.2019.07.441
PG 1
WC Dermatology
SC Dermatology
GA IX4MY
UT WOS:000485661500521
OA Bronze
DA 2020-07-08
ER

PT J
AU Li, DM
   Liang, GZ
   Calderone, R
   Bellanti, JA
AF Li, Dongmei
   Liang, Guanzhao
   Calderone, Richard
   Bellanti, Joseph A.
TI Vitiligo and Hashimoto's thyroiditis: Autoimmune diseases linked by
   clinical presentation, biochemical commonality, and autoimmune/oxidative
   stress-mediated toxicity pathogenesis
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Vitiligo (VL); Hashimoto's thyroiditis (HT); Oxidative stress-mediated
   toxicity; Quinone; Semiquinone; Hydroquinone; Reactive oxygen species
   (ROS)
ID INCREASED PREVALENCE; DISORDERS; DYSFUNCTION; DEFICIENCY; GENERATION;
   CHILDREN; SKIN
AB Vitiligo (VL) is a chronic autoimmune pigmentation disorder characterized by destruction of melanocytes. The condition is associated with several other autoimmune diseases, but autoimmune thyroid diseases, especially Hashimoto's thyroiditis (HT), is the most prevalent organ-specific autoimmune disease with a co-morbidity up to 34%. Among the many hypotheses that have been proposed for the pathogenesis of both diseases, autoimmunity and oxidative stress-mediated toxicity in melanocytes or thyrocytes, respectively, have been the most widely accepted with autoimmunity being the presumed consequence of oxidative stress-mediated toxicity. However, the predominant etiologic basis for impairment of redox balance has rarely been studied. The two autoimmune diseases are not only linked by a concordance of clinical presentations and an autoimmune/oxidative stress mediated toxicity pathogenesis but also by an apparent biochemical commonality. The target molecules produced in the thyroid and skin, i.e., thyroxine and melanin, respectively, are derived from the same primordial parent molecule, tyrosine. On the basis of these similarities between Hashimoto's thyroiditis and vitiligo, specifically with respect to the activation of oxidative stress, we propose a novel hypothesis accounting for the destruction of melanocytes or thyrocytes in VL and AT. We suggest a new therapeutic regimen of quinone derivatives to combat ROS-induced autoimmunity resulting from this common biochemical etiologic error.
C1 [Li, Dongmei; Calderone, Richard; Bellanti, Joseph A.] Georgetown Univ, Med Ctr, Dept Microbiol Immunol, Washington, DC 20057 USA.
   [Liang, Guanzhao] Chinese Acad Med Sci, Dept Mycol, Inst Dermatol, Nanjing, Jiangsu, Peoples R China.
   [Liang, Guanzhao] Peking Union Med Coll, Nanjing, Jiangsu, Peoples R China.
   [Bellanti, Joseph A.] Georgetown Univ, Dept Pediat, Med Ctr, Washington, DC 20057 USA.
RP Bellanti, JA (corresponding author), Georgetown Univ, Med Ctr, Dept Microbiol Immunol, Washington, DC 20057 USA.
EM bellantj@georgetown.edu
CR Bastian TW, 2012, ENDOCRINOLOGY, V153, P5668, DOI 10.1210/en.2012-1067
   Beard JL, 1998, J NUTR, V128, P1401
   Birlea SA, 2011, J INVEST DERMATOL, V131, P371, DOI 10.1038/jid.2010.337
   BOISSY RE, 1991, J INVEST DERMATOL, V97, P395, DOI 10.1111/1523-1747.ep12480976
   Dalsgaard TK, 2013, J AGR FOOD CHEM, V61, P418, DOI 10.1021/jf303973b
   Eletto D, 2014, J CELL SCI, V127, P3649, DOI 10.1242/jcs.153643
   Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7
   FISHER AA, 1994, CUTIS, V53, P278
   Frisoli ML, 2017, J ALLERGY CLIN IMMUN, V140, P654, DOI 10.1016/j.jaci.2017.07.011
   Gill L, 2016, J AM ACAD DERMATOL, V74, P295, DOI 10.1016/j.jaad.2015.08.063
   Kakourou T, 2005, J AM ACAD DERMATOL, V53, P220, DOI 10.1016/j.jaad.2005.03.032
   Karvonen SL, 1999, BRIT J DERMATOL, V140, P634
   Kim H, 2012, ANN DERMATOL, V24, P1, DOI 10.5021/ad.2012.24.1.1
   Li DM, 2011, EUKARYOT CELL, V10, P672, DOI 10.1128/EC.00303-10
   Liu SH, 2008, J ENZYM INHIB MED CH, V23, P526, DOI [10.1080/14756360701654894, 10.1080/14756360701654894 ]
   Loh KC, 2000, POSTGRAD MED J, V76, P133, DOI 10.1136/pmj.76.893.133
   LOWN JW, 1982, BIOCHEM PHARMACOL, V31, P575
   Munoz-Munoz JL, 2009, BBA-PROTEINS PROTEOM, V1794, P1017, DOI 10.1016/j.bbapap.2009.04.002
   MANCINI A, 1989, J ENDOCRINOL INVEST, V12, P511, DOI 10.1007/BF03350748
   Mancini A, 2011, INT J MOL SCI, V12, P9216, DOI 10.3390/ijms12129216
   Mano T, 1998, AM J MED SCI, V315, P230, DOI 10.1097/00000441-199804000-00002
   McLeod DSA, 2012, ENDOCRINE, V42, P252, DOI 10.1007/s12020-012-9703-2
   Mohammed GF, 2015, WORLD J CLIN CASES, V3, P221, DOI 10.12998/wjcc.v3.i3.221
   MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P
   Moncayo R, 2015, BBA CLIN, V3, P44, DOI 10.1016/j.bbacli.2014.11.002
   OLIVER E. A., 1939, Journal of the American Medical Association, V113, P927
   Ongenae K, 2006, J EUR ACAD DERMATOL, V20, P1, DOI 10.1111/j.1468-3083.2005.01369.x
   Ordooei M, 2014, IRAN J PEDIATR HEMAT, V4, P84
   Park K, 2019, FEBS J, V286, P413, DOI 10.1111/febs.14739
   Passi S, 1998, PIGM CELL RES, V11, P81, DOI 10.1111/j.1600-0749.1998.tb00714.x
   PAULING L, 1990, P NATL ACAD SCI USA, V87, P244, DOI 10.1073/pnas.87.1.244
   PORTER J, 1979, GEN HOSP PSYCHIAT, V1, P73, DOI 10.1016/0163-8343(79)90081-1
   Rashighi M, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.11.36
   Tikhomirov AS, 2018, RECENT PAT ANTI-CANC, V13, P159, DOI 10.2174/1574892813666171206123114
   Toda Shuji, 2011, ISRN Endocrinol, V2011, P275782, DOI 10.5402/2011/275782
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Vachiramon V, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7502935
   Vavricka CJ, 2010, PROTEIN CELL, V1, P830, DOI 10.1007/s13238-010-0109-8
   Watanabe N, 2004, METHOD ENZYMOL, V378, P319
   Weetman AP, 2004, AUTOIMMUNITY, V37, P337, DOI 10.1080/08916930410001705394
   Wu SW, 2015, PIGM CELL MELANOMA R, V28, P744, DOI 10.1111/pcmr.12402
NR 41
TC 1
Z9 1
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2019
VL 128
BP 69
EP 75
DI 10.1016/j.mehy.2019.05.010
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA IF8WS
UT WOS:000473374600015
PM 31203913
DA 2020-07-08
ER

PT J
AU Gurpinar, A
   Gunaydin, SD
   Kilic, C
   Karaduman, A
AF Gurpinar, Ahmet
   Gunaydin, Sibel Dogan
   Kilic, Cengiz
   Karaduman, Aysen
TI Association of serum cortisol and dehydroepiandrosterone sulfate (DHEAS)
   levels with psychological stress in patients with vitiligo
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Vitiligo; stress; cortisol; dehydroepiandrosterone sulfate
ID OXIDATIVE STRESS; LIFE EVENTS
AB Background/aim: Vitiligo is a depigmentation disorder that leads to serious psychological burden in patients, who are frequently reported to have depression and anxiety. The aim of this study was to investigate the association between stress-related hormone levels and psychological stress in vitiligo.
   Materials and methods: In this study 46 vitiligo patients and 46 controls were enrolled; their cortisol, dehydroepiandrosterone sulfate (DHEAS), and cortisol/DHEAS levels were measured. Psychological burden was assessed by the Beck Depression Inventory and Perceived Stress Scale.
   Results: Patients and controls did not differ in terms of cortisol, DHEAS, or cortisol/DHEAS. Patients had higher perceived stress than controls but did not differ in terms of depression scores. Correlation analyses revealed that cortisol/DHEAS correlated positively with perceived stress (P = 0.009, r = 0.272). The correlation between cortisol/DHEAS and perceived stress was stronger in the patient group (P = 0.013, r = 0.363) and close to zero among controls. In regression analyses, lower depression and higher perceived stress were shown to predict cortisol/DHEAS values.
   Conclusion: Vitiligo patients significantly differed from the healthy population in terms of hormones and psychological distress. There was also an association between perceived stress and cortisol/DHEAS ratio in vitiligo. Abnormality of hormonal response to distress lowers DHEAS, which is known for its antioxidant properties, a possible mechanism for vitiligo development. Another important finding is the significance of using the composite variable cortisol/DHEAS, which seems to be more sensitive to distress than each of its components. We suggest its use in future studies on psychological distress-hormone relationships.
C1 [Gurpinar, Ahmet; Gunaydin, Sibel Dogan; Karaduman, Aysen] Hacettepe Univ, Fac Med, Dept Dermatol & Venereol, Ankara, Turkey.
   [Kilic, Cengiz] Hacettepe Univ, Fac Med, Dept Psychiat, Ankara, Turkey.
RP Gunaydin, SD (corresponding author), Hacettepe Univ, Fac Med, Dept Dermatol & Venereol, Ankara, Turkey.
EM sibel.dogan@hacettepe.edu.tr
OI Dogan, Sibel/0000-0002-5383-6886; Kilic, Cengiz/0000-0002-9270-8625
FU Hacettepe University Scientific Investigations Unit
FX The Hacettepe University Scientific Investigations Unit funded this
   study.
CR BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Camporez JPG, 2011, J PHYSIOL-LONDON, V589, P2585, DOI 10.1113/jphysiol.2011.206078
   Iannella G, 2016, AUTOIMMUN REV, V15, P335, DOI 10.1016/j.autrev.2015.12.006
   Jia CS, 2011, J TRACE ELEM MED BIO, V25, P154, DOI 10.1016/j.jtemb.2011.04.001
   Kamin HS, 2017, HORM BEHAV, V89, P69, DOI 10.1016/j.yhbeh.2016.11.018
   Manolache L, 2007, J EUR ACAD DERMATOL, V21, P921, DOI 10.1111/j.1468-3083.2006.02106.x
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Picardi A, 2003, PSYCHOTHER PSYCHOSOM, V72, P150, DOI 10.1159/000069731
   Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189
   Wolkowitz O M, 2001, World J Biol Psychiatry, V2, P115
NR 11
TC 2
Z9 2
U1 0
U2 0
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2019
VL 49
IS 3
BP 832
EP 837
DI 10.3906/sag-1812-84
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA ID7ZT
UT WOS:000471902200020
PM 31203593
OA Bronze, Green Published
DA 2020-07-08
ER

PT J
AU Raam, L
   Kaleviste, E
   Sunina, M
   Vaher, H
   Saare, M
   Prans, E
   Pihlap, M
   Abram, K
   Karelson, M
   Peterson, P
   Rebane, A
   Kisand, K
   Kingo, K
AF Raam, Liisi
   Kaleviste, Epp
   Sunina, Marina
   Vaher, Helen
   Saare, Mario
   Prans, Ele
   Pihlap, Maire
   Abram, Kristi
   Karelson, Maire
   Peterson, Part
   Rebane, Ana
   Kisand, Kai
   Kingo, Kulli
TI Lymphoid Stress Surveillance Response Contributes to Vitiligo
   Pathogenesis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE vitiligo; interferons; MICA/MICB; WIPH; LC3; EOMES; B cells; autophagy
ID COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; BLOOD
   MONONUCLEAR-CELLS; CD8(+) T-CELLS; GENERALIZED VITILIGO; SEGMENTAL
   VITILIGO; DISEASE-ACTIVITY; GENE-EXPRESSION; LESIONAL SKIN; MELANOCYTES
AB Vitiligo is a chronic multifactorial depigmentation disorder characterized by the destruction and functional loss of melanocytes. Although a direct cytotoxic T cell attack is thought to be responsible for melanocyte damage, the events leading to the loss of self-tolerance toward melanocytic antigens are not understood. This research aimed to identify novel cellular and molecular factors that participate in vitiligo pathogenesis through the application of gene expression and immunofluorescence analysis of skin biopsy samples along with immunophenotyping of circulating cells. Our study provides insights into the mechanisms involved in melanocyte destruction. The upregulation of stress-ligand MICA/MICB, recognized by activating receptors on innate and innate-like T cells, imply involvement of lymphoid stress surveillance responses in vitiligo lesions. A simultaneous increase in the expression of transcription factor EOMES that is characteristic for innate-like virtual memory T cells, suggest a similar scenario. Local lymphoid stress surveillance has been previously associated with the amplification of systemic humoral responses that were mirrored in our study by increased T follicular helper cells and switched memory B cell proportions in patients with active vitiligo. In addition, microtubule-associated protein light chain 3 staining was compatible with the activation of autophagy in keratinocytes and in the remaining melanocytes of vitiligo lesional skin.
C1 [Raam, Liisi; Abram, Kristi; Karelson, Maire; Kingo, Kulli] Univ Tartu, Dept Dermatol, Tartu, Estonia.
   [Raam, Liisi; Abram, Kristi; Karelson, Maire; Kingo, Kulli] Tartu Univ Hosp, Dermatol Clin, Tartu, Estonia.
   [Kaleviste, Epp; Sunina, Marina; Vaher, Helen; Saare, Mario; Prans, Ele; Pihlap, Maire; Peterson, Part; Rebane, Ana; Kisand, Kai] Univ Tartu, Inst Biomed & Translat Med, Tartu, Estonia.
RP Kingo, K (corresponding author), Univ Tartu, Dept Dermatol, Tartu, Estonia.; Kingo, K (corresponding author), Tartu Univ Hosp, Dermatol Clin, Tartu, Estonia.; Kisand, K (corresponding author), Univ Tartu, Inst Biomed & Translat Med, Tartu, Estonia.
EM kai.kisand@ut.ee; Kylli.Kingo@kliinikum.ee
RI Rebane, Ana/D-4279-2013; Peterson, Part/A-5788-2009; Kisand,
   Kai/J-3483-2015; Saare, Mario/F-1986-2011; Kingo, Kulli/H-3603-2012
OI Rebane, Ana/0000-0001-6051-1361; Peterson, Part/0000-0001-6755-791X;
   Kisand, Kai/0000-0002-5426-4648; Saare, Mario/0000-0003-3372-7700;
   Vaher, Helen/0000-0002-8845-0326
FU European Union through the European Regional Development FundEuropean
   Union (EU) [2012-2015.3.2.0701.12-0049, 2014-2020.4.01.15-0012];
   Estonian Research Council [IUT 2-2];  [PUT1367];  [PUT177];  [PUT1465]; 
   [PUT1669]
FX The research was funded by the European Union through the European
   Regional Development Fund (Project No. 2012-2015.3.2.0701.12-0049 and
   2014-2020.4.01.15-0012), by Estonian Research Council grant IUT 2-2, and
   by personal research grant PUT1367, PUT177, PUT1465 and PUT1669. We
   thank Prof. Annamari Ranki for critical reading of the manuscript and
   valuable comments.
CR Akinduro O, 2016, J INVEST DERMATOL, V136, P1460, DOI 10.1016/j.jid.2016.03.016
   Arya V, 2010, CASE REP DERMATOL, V2, P156, DOI 10.1159/000320207
   Barbarin A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00316
   Bertolotti A, 2014, PIGM CELL MELANOMA R, V27, P398, DOI 10.1111/pcmr.12219
   Boniface K, 2018, J INVEST DERMATOL, V138, P355, DOI 10.1016/j.jid.2017.08.038
   Boniface K, 2018, CLIN REV ALLERG IMMU, V54, P52, DOI 10.1007/s12016-017-8622-7
   Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009
   Crampton SP, 2012, J IMMUNOL, V188, P1451, DOI 10.4049/jimmunol.1102705
   Dahir AM, 2018, INT J DERMATOL, V57, P1157, DOI 10.1111/ijd.14055
   Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7
   Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961
   Ghadially H, 2017, BRIT J CANCER, V116, P1208, DOI 10.1038/bjc.2017.79
   Grimes PE, 2004, J AM ACAD DERMATOL, V51, P52, DOI 10.1016/j.jaad.2003.12.031
   Hamilton JA, 2017, NAT REV DRUG DISCOV, V16, P53, DOI 10.1038/nrd.2016.231
   HARNING R, 1991, J INVEST DERMATOL, V97, P1078, DOI 10.1111/1523-1747.ep12492607
   Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012
   Ho HA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.200543
   Jacquemin C, 2017, BRIT J DERMATOL, V177, P1367, DOI 10.1111/bjd.15550
   Jeong TJ, 2010, EXP DERMATOL, V19, pE323, DOI 10.1111/j.1600-0625.2009.01039.x
   Jian Z, 2014, J INVEST DERMATOL, V134, P2221, DOI 10.1038/jid.2014.152
   Jin Y, 2016, NAT GENET, V48, P1418, DOI 10.1038/ng.3680
   Kemp EH, 2007, AUTOIMMUN REV, V6, P138, DOI 10.1016/j.autrev.2006.09.010
   Kovacs D, 2018, J INVEST DERMATOL, V138, P394, DOI 10.1016/j.jid.2017.06.033
   LePoole IC, 1996, AM J PATHOL, V148, P1219
   Li SL, 2017, J ALLERGY CLIN IMMUN, V140, P177, DOI 10.1016/j.jaci.2016.10.013
   Martinet V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8089
   Mohan GC, 2015, JAMA DERMATOL, V151, P522, DOI 10.1001/jamadermatol.2014.3324
   Moll HP, 2011, CYTOKINE, V53, P52, DOI 10.1016/j.cyto.2010.09.006
   Moretti S, 2002, PIGM CELL RES, V15, P87, DOI 10.1034/j.1600-0749.2002.1o049.x
   Moretti S, 2009, HISTOL HISTOPATHOL, V24, P849, DOI 10.14670/HH-24.849
   Ratsep R, 2008, BRIT J DERMATOL, V159, P1275, DOI 10.1111/j.1365-2133.2008.08785.x
   Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811
   Reemann P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115717
   Regazzetti C, 2015, J INVEST DERMATOL, V135, P3105, DOI 10.1038/jid.2015.335
   Reimann E, 2012, HUM IMMUNOL, V73, P393, DOI 10.1016/j.humimm.2012.01.011
   Richmond JM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7710
   Richmond JM, 2017, J INVEST DERMATOL, V137, P350, DOI 10.1016/j.jid.2016.09.016
   Sandoval-Cruz M, 2011, AUTOIMMUN REV, V10, P762, DOI 10.1016/j.autrev.2011.02.004
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shafi S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002922
   Silverberg JI, 2013, JAMA DERMATOL, V149, P159, DOI 10.1001/jamadermatol.2013.927
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10253-w
   Strassner JP, 2017, J AM ACAD DERMATOL, V76, P847, DOI 10.1016/j.jaad.2016.12.021
   Strid J, 2011, SCIENCE, V334, P1293, DOI 10.1126/science.1211250
   Tembhre MK, 2015, BRIT J DERMATOL, V172, P940, DOI 10.1111/bjd.13511
   Tobin DJ, 2000, J PATHOL, V191, P407
   van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32
   Wang P, 2016, J DERMATOL SCI, V84, P40, DOI 10.1016/j.jdermsci.2016.07.006
   Wang XX, 2016, BRIT J DERMATOL, V174, P1318, DOI 10.1111/bjd.14416
   Xie H, 2016, J DERMATOL SCI, V81, P3, DOI 10.1016/j.jdermsci.2015.09.003
   Yu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051040
   Yu T, 2015, J MOL MED, V93, P31, DOI 10.1007/s00109-014-1225-3
   Yun WJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19914
   Zhang CF, 2015, J INVEST DERMATOL, V135, P1348, DOI 10.1038/jid.2014.439
   Zhou XJ, 2012, AUTOPHAGY, V8, P1286, DOI 10.4161/auto.21212
NR 55
TC 1
Z9 1
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 20
PY 2018
VL 9
AR 2707
DI 10.3389/fimmu.2018.02707
PG 11
WC Immunology
SC Immunology
GA HB0GU
UT WOS:000450692000001
PM 30515176
OA DOAJ Gold, Green Published
DA 2020-07-08
ER

PT J
AU Bastonini, E
   Kovacs, D
   Filoni, A
   Iacovelli, P
   Leone, G
   Picardo, M
AF Bastonini, E.
   Kovacs, D.
   Filoni, A.
   Iacovelli, P.
   Leone, G.
   Picardo, M.
TI Stress-induced autophagy in vitiligo
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology (IID) Meeting
CY MAY 16-19, 2018
CL Orlando, FL
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Bastonini, E.; Kovacs, D.; Filoni, A.; Iacovelli, P.; Leone, G.; Picardo, M.] San Gallicano Dermatol Inst, Rome, Italy.
OI Iacovelli, Paolo/0000-0001-8711-4868
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD SEP
PY 2018
VL 138
IS 9
MA LB1594
BP B21
EP B21
DI 10.1016/j.jid.2018.06.133
PG 1
WC Dermatology
SC Dermatology
GA GR1WC
UT WOS:000442343300121
OA Bronze
DA 2020-07-08
ER

PT J
AU Patel, S
   Rauf, A
   Khan, H
   Meher, BR
   ul Hassan, SS
AF Patel, Seema
   Rauf, Abdur
   Khan, Haroon
   Meher, Biswa Ranjan
   ul Hassan, Syed Shams
TI A holistic review on the autoimmune disease vitiligo with emphasis on
   the causal factors
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Vitiligo; Autoimmune disease; Melanin loss; Thyroid gland; Tyrosine
ID GENERALIZED VITILIGO; OXIDATIVE STRESS; SUBSTRATE-INHIBITION;
   SUSCEPTIBILITY GENE; SEGMENTAL VITILIGO; THYROID-DISEASE; DNA-DAMAGE;
   L-TYROSINE; NB-UVB; SKIN
AB Vitiligo is an idiopathic systemic autoimmune disease affecting skin, hair and oral mucosa. This genetic yet acquired disease characterized by melanin loss is a cause of morbidity across all races. Though thyroid disturbance has been recognized as a key trigger of this pathology, an array of other factors plays critical role in its manifestation. Multiple hormones (corticotropin-releasing hormone, adrenocorticotropic hormone, a-melanocyte-stimulating hormone, melatonin, calcitriol, testosterone, estrogen), genes (Human leukocyte antigen (HLA), Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), Forkhead box D3 (FOXD3), Cluster of differentiation 117 (CD117), Estrogen receptor (ESR) 1, Cyclooxygenase-2 (COX2), Vitiligo-associated protein 1 (VIT1)), and lifestyle choices (stress, diet, cosmetic products, and medications) have been suspected as drivers of this disorder. The pathological mechanisms have been understood in recent times, with the aid of genomic studies; however a universally-effective therapy is yet to be achieved. This review discusses these under-investigated facets of vitiligo onset and progression; hence, it is expected to enrich vitiligo research. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Patel, Seema] San Diego State Univ, Bioinformat & Med Informat Res Ctr, 5500 Campanile Dr, San Diego, CA 92182 USA.
   [Rauf, Abdur] Univ Swabi, Dept Chem, Anbar 23561, Kpk, Pakistan.
   [Khan, Haroon] Abdul Wali Khan Univ, Dept Pharm, Mardan 23200, Pakistan.
   [Meher, Biswa Ranjan] Cent Univ Jharkhand, Ctr Life Sci, Ranchi 835205, Jharkhand, India.
   [ul Hassan, Syed Shams] Zhejiang Univ, Ocean Coll, Dept Marine Chem & Nat Prod, Hangzhou 310058, Zhejiang, Peoples R China.
RP Patel, S (corresponding author), San Diego State Univ, Bioinformat & Med Informat Res Ctr, 5500 Campanile Dr, San Diego, CA 92182 USA.; Rauf, A (corresponding author), Univ Swabi, Dept Chem, Anbar 23561, Kpk, Pakistan.
EM seemabiotech83@gmail.com; mashaljcs@yahoo.com
RI Rauf, Abdur/G-3304-2013; Hassan, Syed Shams ul/I-5382-2019
OI Rauf, Abdur/0000-0003-2429-5491; Hassan, Syed Shams
   ul/0000-0001-5188-6540; Khan, Prof. Dr. Haroon/0000-0002-1736-4404
CR Abraham A, 2014, INDIAN J DERMATOL, V59, P456, DOI 10.4103/0019-5154.139872
   Adebamowo CA, 2008, J AM ACAD DERMATOL, V58, P787, DOI 10.1016/j.jaad.2007.08.049
   Ahad Farhana, 2010, Indian J Endocrinol Metab, V14, P13
   Ahmadieh H, 2013, BIOMED RES INT, DOI 10.1155/2013/725410
   Al-Shobaili HA, 2011, INT J HEALTH SCI-IJH, V5, P167
   Alberts B., 2002, SIGNALING G PROTEIN
   Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x
   Artantas G. S., SKIN FINDINGS THYROI
   Bagherani Nooshin, 2011, Indian J Dermatol, V56, P480, DOI 10.4103/0019-5154.87116
   Bahrami Z, 2009, HORM METAB RES, V41, P762, DOI 10.1055/s-0029-1225629
   Balgir RS, 2013, MEDITERR J HEMATOL I, V5, DOI 10.4084/MJHID.2013.063
   Birlea SA, 2008, ARCH DERMATOL, V144, P310, DOI 10.1001/archderm.144.3.310
   Brenner Michaela, 2008, Drug Discov Today Dis Mech, V5, pe189, DOI 10.1016/j.ddmec.2008.02.001
   Bulfer SL, 2010, J BIOL CHEM, V285, P10446, DOI 10.1074/jbc.M109.094383
   Burton RL, 2007, J BIOL CHEM, V282, P31517, DOI 10.1074/jbc.M704032200
   Camacho Francisco, 2002, J Drugs Dermatol, V1, P127
   Carlson JA, 2007, DERMATOL CLIN, V25, P541, DOI 10.1016/j.det.2007.06.005
   Castro-Ferreira R, 2011, ARQ BRAS CARDIOL, V96, P332, DOI 10.1590/S0066-782X2011005000023
   Ch'ng CL, 2007, CLIN MED RES, V5, P184, DOI 10.3121/cmr.2007.738
   Chen CH, 2014, PHYSIOL REV, V94, P1, DOI 10.1152/physrev.00017.2013
   Cichorek M, 2013, POSTEP DERM ALERGOL, V30, P30, DOI 10.5114/pdia.2013.33376
   Cohen BE, 2015, AM J CLIN DERMATOL, V16, P463, DOI 10.1007/s40257-015-0153-5
   Coondoo Arijit, 2014, Indian Dermatol Online J, V5, P416, DOI 10.4103/2229-5178.142483
   Cooper G.M., 2000, CENTRAL ROLE ENZYMES
   Cooper GS, 2009, J AUTOIMMUN, V33, P197, DOI 10.1016/j.jaut.2009.09.008
   Czajkowski R, 2014, POSTEP DERM ALERGOL, V31, P247, DOI 10.5114/pdia.2014.43497
   de Barros JC, 2014, INT J DERMATOL, V53, P842, DOI 10.1111/ijd.12055
   Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265
   Di Nuzzo S, 2010, CLIN EXP DERMATOL, V35, P215, DOI 10.1111/j.1365-2230.2009.03412.x
   Donelan J, 2006, P NATL ACAD SCI USA, V103, P7759, DOI 10.1073/pnas.0602210103
   Doshi Bhavana, 2013, Indian J Dermatol, V58, P396, DOI 10.4103/0019-5154.117323
   Dudda M, 2013, RECENT PATENTS INFLA, V7, P176, DOI 10.2174/1872213X11307020009
   Ebanks JP, 2009, INT J MOL SCI, V10, P4066, DOI 10.3390/ijms10094066
   Ezzedine K, 2012, PIGM CELL MELANOMA R, V25, pE1, DOI 10.1111/j.1755-148X.2012.00997.x
   Falabella Rafael, 2009, Indian J Dermatol, V54, P313, DOI 10.4103/0019-5154.57604
   Fernstrom JD, 2007, J NUTR, V137, p1539S, DOI 10.1093/jn/137.6.1539S
   Fischer TW, 2008, EXP DERMATOL, V17, P713, DOI 10.1111/j.1600-0625.2008.00767.x
   Gallo-Payet N, 2016, J MOL ENDOCRINOL, V56, pT135, DOI 10.1530/JME-15-0257
   Gessl Alois, 2012, Handb Exp Pharmacol, P361, DOI 10.1007/978-3-642-30726-3_17
   Guerra L, 2010, CURR DRUG METAB, V11, P451, DOI 10.2174/138920010791526105
   Hossain C, 2016, J DRUGS DERMATOL, V15, P384
   Hossani-Madani AR, 2010, GIORN ITAL DERMAT V, V145, P57
   Ismail SA, 2014, J DERMATOL TREAT, V25, P205, DOI 10.3109/09546634.2012.762638
   Jin Y, 2010, J INVEST DERMATOL, V130, P774, DOI 10.1038/jid.2009.273
   Julius D, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005991
   Kandaswamy Shakthisri, 2013, Indian J Dermatol, V58, P325, DOI 10.4103/0019-5154.113944
   Kang HY, 2010, ANN DERMATOL, V22, P373, DOI 10.5021/ad.2010.22.4.373
   Kanwar Amrinder Jit, 2012, Indian J Dermatol, V57, P466, DOI 10.4103/0019-5154.103067
   Kazakevich Natalia, 2011, Skin Therapy Lett, V16, P5
   Khandalavala BN, 2014, CASE REP DERMATOL, V6, P283, DOI 10.1159/000370303
   Kose O, 2016, J PERIODONTOL, V87, pE82, DOI 10.1902/jop.2016.150541
   Kroon MW, 2013, J EUR ACAD DERMATOL, V27, P1172, DOI 10.1111/j.1468-3083.2012.04501.x
   Kumar KVSH, 2012, ENDOCR PRACT, V18, P194, DOI 10.4158/EP11205.OR
   Kumar P, 2010, J ADV PHARM TECHNOL, V1, P297, DOI 10.4103/0110-5558.72420
   Laberge G, 2005, PIGM CELL RES, V18, P300, DOI 10.1111/j.1600-0749.2005.00242.x
   Lachenmeier DW, 2008, J OCCUP MED TOXICOL, V3, DOI 10.1186/1745-6673-3-26
   Lee N. J., 2008, DRUG CLASS REV TOPIC
   Lee N. J., 2017, DRUG CLASS REV TOPIC
   Lotti T, 2008, DERMATOL THER, V21, pS20, DOI 10.1111/j.1529-8019.2008.00198.x
   Lynn DD, 2016, ADOLESC HEALTH MED T, V7, P13, DOI 10.2147/AHMT.S55832
   Matin R., 2008, BMJ CLIN EVID, V2008
   McKenzie Shireen N, 2011, JRSM Short Rep, V2, P68, DOI 10.1258/shorts.2011.011034
   Meyer G, 2002, J ENDOCRINOL INVEST, V25, P804, DOI 10.1007/BF03345516
   Miniati A, 2012, INT J IMMUNOPATH PH, V25, P1
   Miot F., 2017, THYROID HORMONE SYNT
   Miot F., 2000, THYROID HORMONE SYNT
   Molnar GA, 2016, CURR MED CHEM, V23, P667, DOI 10.2174/0929867323666160119094516
   Moreira CG, 2015, J ETHNOPHARMACOL, V168, P315, DOI 10.1016/j.jep.2015.03.080
   Namazi MR, 2009, INDIAN J DERMATOL VE, V75, P116, DOI 10.4103/0378-6323.48654
   Natale CA, 2016, ELIFE, V5, DOI 10.7554/eLife.15104
   Nath SK, 2001, AM J HUM GENET, V69, P1401, DOI 10.1086/324470
   Nestor Mark, 2014, J Clin Aesthet Dermatol, V7, P13
   Niederlander N, 2004, EUR J BIOCHEM, V271, P4572, DOI 10.1111/j.1432-1033.2004.04429.x
   Pandve Harsarl T, 2008, Indian J Dermatol, V53, P40, DOI 10.4103/0019-5154.39745
   Park JH, 2014, ANN DERMATOL, V26, P61, DOI 10.5021/ad.2014.26.1.61
   Petersen AB, 2004, MUTAT RES-GEN TOX EN, V560, P173, DOI 10.1016/j.mrgentox.2004.03.002
   Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229
   Prakash Preeti, 2013, Indian Dermatol Online J, V4, P250, DOI 10.4103/2229-5178.115539
   Prindaville B, 2011, INT J PEDIATR ENDOCR, DOI 10.1186/1687-9856-2011-18
   Puri Neerja, 2012, Indian J Dermatol, V57, P247, DOI 10.4103/0019-5154.96227
   Rajatanavin N, 2008, INT J DERMATOL, V47, P402, DOI 10.1111/j.1365-4632.2008.03356.x
   Rao T S Sathyanarayana, 2008, Indian J Psychiatry, V50, P77, DOI 10.4103/0019-5545.42391
   Reed MC, 2010, BIOESSAYS, V32, P422, DOI 10.1002/bies.200900167
   Risbrough VB, 2006, HORM BEHAV, V50, P550, DOI 10.1016/j.yhbeh.2006.06.019
   Rogosic V, 2010, ACTA DERMATOVENER CR, V18, P21
   Rordam Ole Martin, 2012, J Clin Aesthet Dermatol, V5, P36
   Rousseau K, 2007, FASEB J, V21, P1844, DOI 10.1096/fj.06-7398com
   Saraceno R, 2009, DERMATOL THER, V22, P391, DOI 10.1111/j.1529-8019.2009.01252.x
   Sarveswari K N, 2010, Indian J Dermatol, V55, P211, DOI 10.4103/0019-5154.70663
   Schallreuter KU, 2013, FASEB J, V27, P3113, DOI 10.1096/fj.12-226779
   Schlumpf M, 2010, DERM-ENDOCRINOL, V2, P19, DOI 10.4161/derm.2.1.12016
   Sendur N, 2006, J DERMATOL TREAT, V17, P338, DOI 10.1080/09546630601028711
   Shahmoradi Z, 2013, INT J PREVENTIVE MED, V4, P200
   Shin JW, 2010, ANN DERMATOL, V22, P279, DOI 10.5021/ad.2010.22.3.279
   Silverberg JI, 2015, CUTIS, V95, P255
   Singh AK, 2010, J PLAST RECONSTR AES, V63, P988, DOI 10.1016/j.bjps.2009.03.013
   Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007
   Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x
   Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004
   Smith AG, 2010, J INVEST DERMATOL, V130, P643, DOI 10.1038/jid.2009.403
   Smith Sean M, 2006, Dialogues Clin Neurosci, V8, P383
   Song TR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003173
   Spritz RA, 2011, J GENET GENOMICS, V38, P271, DOI 10.1016/j.jgg.2011.05.005
   Spritz RA, 2010, THYROID, V20, P745, DOI 10.1089/thy.2010.1643
   Stanimirovic A, 2016, DERMATOL THER, V29, P312, DOI 10.1111/dth.12363
   Sukan M, 2007, J SEX MARITAL THER, V33, P55, DOI 10.1080/00926230600998482
   Szczurko O, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-21
   TROMBITAS K, 1995, CIRC RES, V77, P856, DOI 10.1161/01.RES.77.4.856
   Van Driessche F, 2015, PEDIATR DRUGS, V17, P303, DOI 10.1007/s40272-015-0135-3
   VEDALDI D, 1988, FARMACO, V43, P333
   Verma Indu, 2012, Int J Appl Basic Med Res, V2, P17, DOI 10.4103/2229-516X.96795
   Vikhlyantsev IM, 2012, BIOCHEMISTRY-MOSCOW+, V77, P1515, DOI 10.1134/S0006297912130093
   Wang SQ, 2015, EXP DERMATOL, V24, P298, DOI 10.1111/exd.12621
   Wang ZH, 2012, NEURAL REGEN RES, V7, P1413, DOI 10.3969/j.issn.1673-5374.2012.18.008
   Wassef C, 2013, J DRUGS DERMATOL, V12, P685
   Williams HJ, 2007, SCHIZOPHRENIA BULL, V33, P635, DOI 10.1093/schbul/sbm019
   Wong R, 2013, INT J DERMATOL, V52, P491, DOI 10.1111/j.1365-4632.2012.05697.x
   Xie H, 2016, J DERMATOL SCI, V81, P3, DOI 10.1016/j.jdermsci.2015.09.003
   Yaghoobi R, 2011, J DERMATOL, V38, P419, DOI 10.1111/j.1346-8138.2010.01139.x
   Yamamoto H, 2015, SCI REP-UK, V5, DOI 10.1038/srep14579
   Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637
   Zhang Z, 2009, ARCH DERMATOL RES, V301, P167, DOI 10.1007/s00403-008-0900-z
NR 122
TC 10
Z9 11
U1 0
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD AUG
PY 2017
VL 92
BP 501
EP 508
DI 10.1016/j.biopha.2017.05.095
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FE0MY
UT WOS:000407915600058
PM 28575807
DA 2020-07-08
ER

PT J
AU Grimes, PE
   Nashawati, R
AF Grimes, Pearl E.
   Nashawati, Rama
TI The Role of Diet and Supplements in Vitiligo Management
SO DERMATOLOGIC CLINICS
LA English
DT Article
DE Vitiligo; Autoimmune disease; Oxidative stress; Vitamin D; Vitamins;
   Polypodium leucotomos; Ginkgo biloba; EGCG
ID POLYPODIUM-LEUCOTOMOS EXTRACT; NARROW-BAND-UVB; AUTOIMMUNE-DISEASES;
   FOLIC-ACID; VITAMIN-E; MELANOCYTE PROLIFERATION; CLINICAL-TRIAL;
   GINKGO-BILOBA; PIPERINE; ANTIOXIDANTS
AB Vitiligo is an autoimmune disorder that involves the interplay between oxidative stress and the immune system. Preliminary observations suggest that the presence of gluten in the diet may play a role in vitiligo development in some patients, but to date vitiligo-specific diets have not been studied. The role of oral supplements, including vitamins, minerals, and botanicals, is increasingly being investigated as adjuncts to conventional medical treatment due to their antioxidant and immunomodulatory activity. Studies suggest that many of these agents may have some efficacy as monotherapy, but more often as adjuncts to topical agents and phototherapy.
C1 [Grimes, Pearl E.] Univ Calif Los Angeles, Div Dermatol, Vitiligo & Pigmentat Inst Southern Calif, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
   [Grimes, Pearl E.; Nashawati, Rama] Vitiligo & Pigmentat Inst Southern Calif, 5670 Wilshire Blvd,650, Los Angeles, CA 90036 USA.
RP Grimes, PE (corresponding author), Univ Calif Los Angeles, Div Dermatol, Vitiligo & Pigmentat Inst Southern Calif, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.; Grimes, PE (corresponding author), Vitiligo & Pigmentat Inst Southern Calif, 5670 Wilshire Blvd,650, Los Angeles, CA 90036 USA.
EM pegrimesmd@aol.com
CR Akyol M, 2002, EUR J DERMATOL, V12, P24
   AlGhamdi K, 2013, INDIAN J DERMATOL VE, V79, P750, DOI 10.4103/0378-6323.120720
   Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j
   [Anonymous], 2016, PROP MECH ACT GINKG
   Bagherani Nooshin, 2011, Indian J Dermatol, V56, P480, DOI 10.4103/0019-5154.87116
   Balci DD, 2009, EUR J DERMATOL, V19, P382, DOI 10.1684/ejd.2009.0671
   Bhattacharya A, 1999, INDIAN J EXPT BIOL, V37, P676
   Bhattacharya S K, 1981, Indian J Dermatol, V26, P4
   BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035
   Colucci R, 2015, ARCH ENVIRON CON TOX, V69, P181, DOI 10.1007/s00244-015-0138-7
   Colucci R, 2015, DERMATOL THER, V28, P17, DOI 10.1111/dth.12172
   Dang GK, 2011, PHYTOTHER RES, V25, P904, DOI 10.1002/ptr.3345
   Dell'Anna ML, 2007, CLIN EXP DERMATOL, V32, P631, DOI 10.1111/j.1365-2230.2007.02514.x
   Dell'Anna ML, 2001, J INVEST DERMATOL, V117, P908, DOI 10.1046/j.0022-202x.2001.01459.x
   Dusso AS, 2004, SEMIN NEPHROL, V24, P10, DOI 10.1053/j.semnephrol.2003.08.018
   Elgoweini M, 2009, J CLIN PHARMACOL, V49, P852, DOI 10.1177/0091270009335769
   Ezzedine K, 2012, PIGM CELL MELANOMA R, V25, pE1, DOI 10.1111/j.1755-148X.2012.00997.x
   Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7
   Faas L, 2008, BRIT J DERMATOL, V158, P941, DOI 10.1111/j.1365-2133.2008.08464.x
   Finamor DC, 2013, DERM-ENDOCRINOL, V5, DOI 10.4161/derm.24808
   Gonul M, 2010, INDIAN J DERMATOL VE, V76, DOI 10.4103/0378-6323.66611
   Grimes PE, 2005, JAMA-J AM MED ASSOC, V293, P730, DOI 10.1001/jama.293.6.730
   Grimes PE, 2004, J AM ACAD DERMATOL, V51, pS5, DOI 10.1016/j.jaad.2004.01.007
   Grimes PE, 2016, VITILIGO PATHOGENESI
   Habib-Ur-Rehman, 2007, NAT PROD RES, V21, P775, DOI 10.1080/14786410601124664
   Juhlin L, 1997, ACTA DERM-VENEREOL, V77, P460
   Khandalavala BN, 2014, CASE REP DERMATOL, V6, P283, DOI 10.1159/000370303
   Kim SM, 1999, YONSEI MED J, V40, P195, DOI 10.3349/ymj.1999.40.3.195
   Lin ZX, 1999, PLANTA MED, V65, P600, DOI 10.1055/s-1999-14031
   Mandelcorn-Monson RL, 2003, J INVEST DERMATOL, V121, P550, DOI 10.1046/j.1523-1747.2003.12413.x
   Palomino OM, 2015, ARCH DERMATOL RES, V307, P199, DOI 10.1007/s00403-014-1535-x
   Middelkamp-Hup MA, 2007, J EUR ACAD DERMATOL, V21, P942, DOI 10.1111/j.1468-3083.2006.02132.x
   Middelkamp-Hup MA, 2004, J AM ACAD DERMATOL, V51, P910, DOI 10.1016/j.jaad.2004.06.027
   MOHAMMAD A, 1989, INT J DERMATOL, V28, P479
   Mohammed GF, 2015, WORLD J CLIN CASES, V3, P221, DOI 10.12998/wjcc.v3.i3.221
   MONTES LF, 1992, CUTIS, V50, P39
   MORRONE A, 1992, PIGM CELL RES, V5, P65, DOI 10.1111/j.1600-0749.1992.tb00003.x
   Namazi MR, 2009, INDIAN J DERMATOL VE, V75, P116, DOI 10.4103/0378-6323.48654
   Nestor Mark, 2014, J Clin Aesthet Dermatol, V7, P13
   Ongenae K, 2003, PIGM CELL RES, V16, P90, DOI 10.1034/j.1600-0749.2003.00023.x
   Ortonne JP, 2008, SURG MANAGEMENT VITI, P4
   Parsad D, 2003, CLIN EXP DERMATOL, V28, P285, DOI 10.1046/j.1365-2230.2003.01207.x
   Picardo M, 1996, J INVEST DERMATOL, V107, P322, DOI 10.1111/1523-1747.ep12363163
   PRASAD AS, 1995, NUTRITION, V11, P93
   Ramadan S, 2013, SKIN PHARMACOL PHYS, V26, P2, DOI 10.1159/000342124
   Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811
   Reyes E, 2006, J DERMATOL SCI, V41, P213, DOI 10.1016/j.jdermsci.2005.12.006
   Rodriguez-Garcia C, 2011, PEDIATR DERMATOL, V28, P209, DOI 10.1111/j.1525-1470.2011.01388.x
   Saleh HMA, 2013, PHOTODERMATOL PHOTO, V29, P34, DOI 10.1111/phpp.12016
   Shahmoradi Z, 2013, INT J PREVENTIVE MED, V4, P200
   Shameer P, 2005, Indian J Dermatol Venereol Leprol, V71, P206
   Silverberg JI, 2010, J AM ACAD DERMATOL, V62, P937, DOI 10.1016/j.jaad.2009.11.024
   Soumyanath A, 2006, PHOTOCHEM PHOTOBIOL, V82, P1541, DOI 10.1111/j.1751-1097.2006.tb09809.x
   Szczurko O, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-21
   Tjioe M, 2002, ACTA DERM-VENEREOL, V82, P369, DOI 10.1080/000155502320624113
   Venkatasamy R, 2004, BIOORGAN MED CHEM, V12, P1905, DOI 10.1016/j.bmc.2004.01.036
   Winkelmann RR, 2015, J DRUGS DERMATOL, V14, P254
   Wu DY, 2012, MOL ASPECTS MED, V33, P107, DOI 10.1016/j.mam.2011.10.001
   Xu X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052778
   Yaghoobi R, 2011, BMC DERMATOL, V11, DOI 10.1186/1471-5945-11-7
   Yoon J., 2011, VITILIGO MANAGEMENT
   Zhu YP, 2014, FITOTERAPIA, V99, P243, DOI 10.1016/j.fitote.2014.08.007
NR 62
TC 5
Z9 5
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8635
EI 1558-0520
J9 DERMATOL CLIN
JI Dermatol. Clin.
PD APR
PY 2017
VL 35
IS 2
BP 235
EP +
DI 10.1016/j.det.2016.11.012
PG 11
WC Dermatology
SC Dermatology
GA ES6DV
UT WOS:000399637500014
PM 28317532
DA 2020-07-08
ER

PT J
AU Shaker, OG
   Eltahlawi, SMR
   Tawfic, SO
   Eltawdy, AM
   Bedair, NIE
AF Shaker, O. G.
   Eltahlawi, S. M. R.
   Tawfic, S. O.
   Eltawdy, A. M.
   Bedair, N. I. E.
TI Corticotropin-releasing hormone (CRH) and CRH receptor 1 gene expression
   in vitiligo
SO CLINICAL AND EXPERIMENTAL DERMATOLOGY
LA English
DT Article
ID PITUITARY-ADRENAL AXIS; MELANOCYTE-STIMULATING HORMONE;
   NECROSIS-FACTOR-ALPHA; ALOPECIA-AREATA; SKIN BIOPSIES; STRESS;
   INTERLEUKIN-1-ALPHA; MECHANISMS; PSORIASIS; SYSTEM
AB BackgroundVitiligo is a disorder characterized by depigmented patches in the skin. Psychological stress can activate the hypothalamic-pituitary-adrenal axis in the brain as well as on the peripheral level and aggravate autoimmune skin diseases. Skin appendages have dual functions dually as prominent targets and sources of the peripheral corticotropin-releasing hormone (CRH)-proopiomelanocortin axis.
   AimTo assess the role of CRH and CRHR-1 in vitiligo, and its possible association with psychological stress.
   MethodsIn total, 30 patients with vitiligo and 30 healthy controls were collected from the outpatient clinic. Expression of CRH and CRHR-1 was measured by real-time PCR in lesions and control skin.
   ResultsA significant increase in CRH and CRHR-1 expression was significantly correlated with psychological stress in vitiligo.
   ConclusionWe conclude that CRH and CRHR-1 are altered by psychological stress and play an important role in the pathogenesis of vitiligo.
C1 [Shaker, O. G.] Cairo Univ, Fac Med, Dept Biochem Med Biochem & Mol Biol, Cairo, Egypt.
   [Eltahlawi, S. M. R.; Tawfic, S. O.; Eltawdy, A. M.] Cairo Univ, Fac Med, Dept Dermatol, Cairo, Egypt.
   [Bedair, N. I. E.] Cairo Univ, Students Hosp, Dept Dermatol, Cairo, Egypt.
RP Shaker, OG (corresponding author), Cairo Univ, Fac Med, Dept Med Biochem, Cairo 0123, Egypt.
EM olfatshaker@yahoo.com
RI Shaker, Olfat G/S-2010-2017; O, Shaker/Y-6125-2019
OI O, Shaker/0000-0002-3031-3599
CR Birol A, 2006, INT J DERMATOL, V45, P992, DOI 10.1111/j.1365-4632.2006.02744.x
   Cucchi ML, 2010, PIGMENT CELL RES, V13, P28
   Funasaka Y, 1998, BRIT J DERMATOL, V139, P216
   Ganceviciene R, 2009, BRIT J DERMATOL, V160, P345, DOI 10.1111/j.1365-2133.2008.08959.x
   HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
   Karanikas Evangelos, 2007, Hormones (Athens), V6, P314
   Katsarou-Katsari A, 2001, DERMATOLOGY, V203, P157, DOI 10.1159/000051732
   Kim HS, 2006, EXP DERMATOL, V15, P515, DOI 10.1111/j.1600-0625.2006.00443.x
   Manolache L, 2007, J EUR ACAD DERMATOL, V21, P921, DOI 10.1111/j.1468-3083.2006.02106.x
   MORRONE A, 1992, PIGM CELL RES, V5, P65, DOI 10.1111/j.1600-0749.1992.tb00003.x
   Peters EMJ, 2006, EXP DERMATOL, V15, P1, DOI 10.1111/j.0906-6705.2005.00372.x
   Ratsep R, 2008, BRIT J DERMATOL, V159, P1275, DOI 10.1111/j.1365-2133.2008.08785.x
   Reimann E, 2010, J DERMATOL SCI, V60, P125, DOI 10.1016/j.jdermsci.2010.08.004
   Richards HL, 2005, BRIT J DERMATOL, V153, P1114, DOI 10.1111/j.1365-2133.2005.06817.x
   SALZER BA, 1995, DERMATOLOGY, V190, P109, DOI 10.1159/000246657
   SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658
   Slominski A, 2000, PHYSIOL REV, V80, P279
   Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012
   Slominski A, 2013, J STEROID BIOCHEM, V137, P107, DOI 10.1016/j.jsbmb.2013.02.006
   Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966
   Slominski AT, 2013, ENDOCR REV, V34, P827, DOI 10.1210/er.2012-1092
   Sullivan RM, 2006, BRAIN RES, V1076, P49, DOI 10.1016/j.brainres.2005.12.100
   Tagen M, 2007, J INVEST DERMATOL, V127, P1789, DOI 10.1038/sj.jid.5700757
   Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4
   Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1
NR 25
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0307-6938
EI 1365-2230
J9 CLIN EXP DERMATOL
JI Clin. Exp. Dermatol.
PD OCT
PY 2016
VL 41
IS 7
BP 734
EP 740
DI 10.1111/ced.12907
PG 7
WC Dermatology
SC Dermatology
GA DY0WO
UT WOS:000384817100005
PM 27663146
DA 2020-07-08
ER

PT J
AU Jha, A
   Mehta, M
   Khaitan, BK
   Sharma, VK
   Ramam, M
AF Jha, Aditi
   Mehta, Manju
   Khaitan, Binod K.
   Sharma, Vinod K.
   Ramam, M.
TI Cognitive behavior therapy for psychosocial stress in vitiligo
SO INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
LA English
DT Letter
ID PSORIASIS
C1 [Jha, Aditi; Khaitan, Binod K.; Sharma, Vinod K.; Ramam, M.] All India Inst Med Sci, Dept Dermatol & Venereol, 4th Floor,Teaching Block, New Delhi, India.
   [Mehta, Manju] All India Inst Med Sci, Dept Psychiat, New Delhi, India.
RP Ramam, M (corresponding author), All India Inst Med Sci, Dept Dermatol & Venereol, 4th Floor,Teaching Block, New Delhi, India.
EM mramam@hotmail.com
CR Fortune DG, 2004, BRIT J CLIN PSYCHOL, V43, P65, DOI 10.1348/014466504772812977
   Fortune DG, 2002, BRIT J DERMATOL, V146, P458, DOI 10.1046/j.1365-2133.2002.04622.x
   Pahwa P, 2013, INDIAN J DERMATOL VE, V79, P679, DOI 10.4103/0378-6323.116737
   Papadopoulos L, 1999, BRIT J MED PSYCHOL, V72, P385, DOI 10.1348/000711299160077
   Papadopoulos L, 2004, DERMATOL PSYCHOSOM, V5, P172, DOI [DOI 10.1159/000083091, 10.1159/000083091]
   PRICE ML, 1991, CLIN EXP DERMATOL, V16, P114, DOI 10.1111/j.1365-2230.1991.tb00319.x
NR 6
TC 5
Z9 5
U1 0
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0378-6323
EI 0973-3922
J9 INDIAN J DERMATOL VE
JI Indian J. Dermatol. Venereol. Leprol.
PD MAY-JUN
PY 2016
VL 82
IS 3
BP 308
EP U154
DI 10.4103/0378-6323.175925
PG 3
WC Dermatology
SC Dermatology
GA DJ9IH
UT WOS:000374526700011
PM 27088935
OA DOAJ Gold
DA 2020-07-08
ER

PT J
AU Bonotis, K
   Pantelis, K
   Karaoulanis, S
   Katsimaglis, C
   Papaliaga, M
   Zafiriou, E
   Tsogas, P
AF Bonotis, Konstantinos
   Pantelis, Konstantinos
   Karaoulanis, Sokratis
   Katsimaglis, Chrysanthos
   Papaliaga, Maria
   Zafiriou, Efterpi
   Tsogas, Panagiotis
TI Investigation of factors associated with health-related quality of life
   and psychological distress in vitiligo
SO JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
LA English
DT Article
ID PERSONALITY; EXPERIENCE
AB Background and objectives: Skin diseases distort the body image with possible negative effects on the quality of life and psychosocial health of patients. While vitiligo does not affect the physical well-being, it may be psychologically distressing. The present study was based on the hypothesis that particular factors might be critical regarding the adjustment to the disease.
   Patients and Methods: We investigated the vitiligo-related quality of life and psychological distress of 216 patients diagnosed with the disease in relation to demographic factors, disease components, and personality traits. For this purpose, we administered the self-completed questionnaires Dermatological Quality of Life Index, General Health Questionnaire, Eysenck Personality Inventory, and Rosenberg Self-Esteem Scale.
   Results: Statistical analysis revealed a significant positive correlation between patients' distress and health-related quality of life. Moreover, the impact of vitiligo on the quality of life was significantly associated with disease variables as well as personality traits and gender. On the other hand, psychological distress was significantly associated with personality traits and gender, but not with disease components.
   Conclusions: Our results indicate that the psychosocial adjustment to the disease is mainly influenced by subjective factors. This observation could imply the need for targeted support interventions in the treatment of vitiligo.
C1 [Bonotis, Konstantinos; Pantelis, Konstantinos; Karaoulanis, Sokratis; Katsimaglis, Chrysanthos; Papaliaga, Maria; Tsogas, Panagiotis] Univ Thessaly, Dept Psychiat, Fac Med, Biopolis 41110, Larisa, Greece.
   [Zafiriou, Efterpi] Univ Thessaly, Dept Dermatol, Fac Med, Biopolis 41110, Larisa, Greece.
   [Tsogas, Panagiotis] Vitiligo Ctr Clin, Athens, Greece.
RP Bonotis, K (corresponding author), Univ Thessaly, Dept Psychiat, Fac Med, Biopolis 41110, Larisa, Greece.
EM kbonotis@yahoo.gr
OI Zafiriou, Efterpi/0000-0002-6594-7292
CR Alikhan A, 2011, J AM ACAD DERMATOL, V65, P473, DOI 10.1016/j.jaad.2010.11.061
   Borimnejad Leili, 2006, Gend Med, V3, P124, DOI 10.1016/S1550-8579(06)80201-9
   Chan MF, 2012, J CLIN NURS, V21, P1614, DOI 10.1111/j.1365-2702.2011.03777.x
   Connor-Smith JK, 2007, J PERS SOC PSYCHOL, V93, P1080, DOI 10.1037/0022-3514.93.6.1080
   DIMITRIOU EC, 1978, INT J INTERCULTURAL, V2, P266
   FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x
   Fistaro SK, 2010, J DTSCH DERMATOL GES, V8, P187, DOI 10.1111/j.1610-0387.2009.07137.x
   Forschner Tobias, 2007, J Dtsch Dermatol Ges, V5, P467, DOI 10.1111/j.1610-0387.2007.06280.x
   GARYFALLOS G, 1991, ACTA PSYCHIAT SCAND, V84, P371, DOI 10.1111/j.1600-0447.1991.tb03162.x
   Homan MWL, 2009, J AM ACAD DERMATOL, V61, P411, DOI 10.1016/j.jaad.2009.03.022
   Kostopoulou P, 2009, BRIT J DERMATOL, V161, P128, DOI 10.1111/j.1365-2133.2009.09077.x
   Lahey BB, 2009, AM PSYCHOL, V64, P241, DOI 10.1037/a0015309
   Lipowski ZJ, 1985, PSYCHOSOMATIC MED LI, P141
   MCCRAE RR, 1986, J PERS, V54, P385, DOI 10.1111/j.1467-6494.1986.tb00401.x
   Ongenae K, 2005, BRIT J DERMATOL, V152, P1165, DOI 10.1111/j.1365-2133.2005.06456.x
   PAPADOPOULOS L, 2002, PSYCHOLOGY, V7, P425
   Parsad Davinder, 2003, Health Qual Life Outcomes, V1, P58, DOI 10.1186/1477-7525-1-58
   PORTER J, 1979, GEN HOSP PSYCHIAT, V1, P73, DOI 10.1016/0163-8343(79)90081-1
   Sampogna F, 2008, BRIT J DERMATOL, V159, P351, DOI 10.1111/j.1365-2133.2008.08678.x
   Schmid-Ott G, 2007, J EUR ACAD DERMATOL, V21, P456, DOI 10.1111/j.1468-3083.2006.01897.x
   Schmitt DP, 2005, J PERS SOC PSYCHOL, V89, P623, DOI 10.1037/0022-3514.89.4.623
   Swami V, 2008, BODY IMAGE, V5, P322, DOI 10.1016/j.bodyim.2008.03.007
   Thompson A. R., 2005, PSYCHODERMATOLOGY PS, P57
   Wood-Barcalow NL, 2010, BODY IMAGE, V7, P106, DOI 10.1016/j.bodyim.2010.01.001
NR 24
TC 6
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1610-0379
EI 1610-0387
J9 J DTSCH DERMATOL GES
JI J. Dtsch. Dermatol. Ges.
PD JAN
PY 2016
VL 14
IS 1
BP 45
EP 48
DI 10.1111/ddg.12729
PG 4
WC Dermatology
SC Dermatology
GA DA4QT
UT WOS:000367786100006
PM 26713637
DA 2020-07-08
ER

PT J
AU Harris, JE
AF Harris, John E.
TI Cellular stress and innate inflammation in organ-specific autoimmunity:
   lessons learned from vitiligo
SO IMMUNOLOGICAL REVIEWS
LA English
DT Review
DE cellular stress; innate immunity; organ-specific autoimmunity; vitiligo
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE;
   THIOREDOXIN-INTERACTING PROTEIN; HYDROGEN-PEROXIDE H2O2;
   MULTIPLE-SCLEROSIS; OXIDATIVE STRESS; HUMAN MELANOCYTES; T-CELLS;
   GENERALIZED VITILIGO; DOUBLE-BLIND
AB For decades, research in autoimmunity has focused primarily on immune contributions to disease. Yet recent studies report elevated levels of reactive oxygen species and abnormal activation of the unfolded protein response in cells targeted by autoimmunity, implicating cellular stress originating from the target tissue as a contributing factor. A better understanding of this contribution may help to answer important lingering questions in organ-specific autoimmunity, as to what factors initiate disease and what directs its tissue specificity. Vitiligo, an autoimmune disease of the skin, has been the focus of translational research for over 30 years, and both melanocyte stress and immune mechanisms have been thought to be mutually exclusive explanations for pathogenesis. Chemical-induced vitiligo is a unique clinical presentation that reflects the importance of environmental influences on autoimmunity, provides insight into a new paradigm linking cell stress to the immune response, and serves as a template for other autoimmune diseases. In this review, I will discuss the evidence for cell stress contributions to a number of autoimmune diseases, the questions that remain, and how vitiligo, an underappreciated example of organ-specific autoimmunity, helps to answer them.
C1 [Harris, John E.] Univ Massachusetts, Sch Med, Dept Med, Div Dermatol, Worcester, MA 01605 USA.
RP Harris, JE (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Dermatol, 225 LRB,364 Plantat St, Worcester, MA 01605 USA.
EM john.harris@umassmed.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [AR061437]; Vitiligo Research
   Foundation; Kawaja Family Vitiligo Research Initiative Award;
   Dermatology Foundation Stiefel Scholar Award
FX This work was supported by the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases, part of the NIH, under award number
   AR061437, and research grants from the Vitiligo Research Foundation,
   Kawaja Family Vitiligo Research Initiative Award, and Dermatology
   Foundation Stiefel Scholar Award. The author states that he has no
   conflicts of interest.
CR Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Agarwal P, 2015, J INVEST DERMATOL, V135, P1080, DOI 10.1038/jid.2014.529
   Akay BN, 2010, J EUR ACAD DERMATOL, V24, P1144, DOI 10.1111/j.1468-3083.2010.03605.x
   Alajlan A, 2002, J AM ACAD DERMATOL, V46, P606, DOI 10.1067/mjd.2002.117215
   Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x
   Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Antonelli A, 2015, AUTOIMMUN REV, V14, P174, DOI 10.1016/j.autrev.2014.10.016
   Au WY, 2001, BRIT J DERMATOL, V145, P1015, DOI 10.1046/j.1365-2133.2001.04500.x
   Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770
   BETTERLE C, 1979, ARCH DERMATOL, V115, P364, DOI 10.1001/archderm.115.3.364
   Birlea SA, 2011, J INVEST DERMATOL, V131, P371, DOI 10.1038/jid.2010.337
   BOISSY RE, 1991, J INVEST DERMATOL, V97, P395, DOI 10.1111/1523-1747.ep12480976
   Bottino R, 2002, DIABETES, V51, P2561, DOI 10.2337/diabetes.51.8.2561
   Brent GA, 2010, THYROID, V20, P755, DOI 10.1089/thy.2010.1636
   Brix TH, 2012, CLIN ENDOCRINOL, V76, P457, DOI 10.1111/j.1365-2265.2011.04318.x
   Burek CL, 2008, AUTOIMMUN REV, V7, P530, DOI 10.1016/j.autrev.2008.04.006
   Cabrera SM, 2016, TRANSL RES, V167, P214, DOI 10.1016/j.trsl.2015.04.011
   Campbell GR, 2011, ANN NEUROL, V69, P481, DOI 10.1002/ana.22109
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Colombo C, 2008, J CLIN INVEST, V118, P2148, DOI 10.1172/JCI33777
   Committee TADC, 2005, REP C PROGR AUT DIS
   Corthals AP, 2011, Q REV BIOL, V86, P287, DOI 10.1086/662453
   Cotsapas C, 2013, TRENDS IMMUNOL, V34, P22, DOI 10.1016/j.it.2012.09.001
   Craiglow BG, 2015, JAMA DERMATOL, V151, P1110, DOI 10.1001/jamadermatol.2015.1520
   CUNLIFFE WJ, 1968, BRIT J DERMATOL, V80, P135, DOI 10.1111/j.1365-2133.1968.tb12282.x
   Cunnea P, 2011, MULT SCLER J, V17, P808, DOI 10.1177/1352458511399114
   Danese S, 2015, GUT, V64, P243, DOI 10.1136/gutjnl-2014-308004
   Dell'Anna ML, 2007, CLIN EXP DERMATOL, V32, P631, DOI 10.1111/j.1365-2230.2007.02514.x
   Dell'Anna ML, 2007, J INVEST DERMATOL, V127, P1226, DOI 10.1038/sj.jid.5700700
   Dell'Anna ML, 2012, EXP DERMATOL, V21, P490, DOI 10.1111/j.1600-0625.2012.01506.x
   Eizirik DL, 2013, DIABETOLOGIA, V56, P234, DOI 10.1007/s00125-012-2762-3
   Elia PP, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/936193
   Engin F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006534
   Fischer MT, 2013, BRAIN, V136, P1799, DOI 10.1093/brain/awt110
   Frigerio S, 2002, NAT MED, V8, P1414, DOI 10.1038/nm792
   Frischer JM, 2009, BRAIN, V132, P1175, DOI 10.1093/brain/awp070
   Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836
   Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1
   Gawkrodger DJ, 2009, BRIT J DERMATOL, V161, P721, DOI 10.1111/j.1365-2133.2009.09292.x
   Ghosh S, 2009, BRIT J DERMATOL, V160, P40, DOI 10.1111/j.1365-2133.2008.08815.x
   Gibbons NQ, 2006, J INVEST DERMATOL, V126, P2576, DOI 10.1038/sj.jid.5700612
   Gilgun-Sherki Y, 2004, J NEUROL, V251, P261, DOI 10.1007/s00415-004-0348-9
   GILHAR A, 1995, J INVEST DERMATOL, V105, P683, DOI 10.1111/1523-1747.ep12324456
   GILHAR A, 1989, ARCH DERMATOL, V125, P1363, DOI 10.1001/archderm.125.10.1363
   Glassman SJ, 2011, CLIN SCI, V120, P99, DOI 10.1042/CS20090603
   Goris A, 2012, COLD SPRING HARB PER, V4, P1
   Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006
   Hansen PS, 2006, EUR J ENDOCRINOL, V154, P29, DOI 10.1530/eje.1.02060
   Harris JE, 2015, J AM ACAD DERMATOL
   Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463
   Hasnain SZ, 2012, IMMUNOL CELL BIOL, V90, P260, DOI 10.1038/icb.2011.112
   Hernandez-Pedro NY, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/413465
   HERTZ KC, 1977, NEW ENGL J MED, V297, P634, DOI 10.1056/NEJM197709222971204
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Higa A, 2012, CELL SIGNAL, V24, P1548, DOI 10.1016/j.cellsig.2012.03.011
   Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   HUNTER MIS, 1985, NEUROCHEM RES, V10, P1645, DOI 10.1007/BF00988606
   Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304
   Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412
   Jimbow K, 2001, BRIT J DERMATOL, V144, P55, DOI 10.1046/j.1365-2133.2001.03952.x
   Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592
   Jin Y, 2012, J INVEST DERMATOL, V132, P1730, DOI 10.1038/jid.2012.37
   Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Koca R, 2004, CLIN EXP DERMATOL, V29, P406, DOI 10.1111/j.1365-2230.2004.01524.x
   Kroll TM, 2005, J INVEST DERMATOL, V124, P798, DOI 10.1111/j.0022-202X.2005.23653.x
   Kroon MW, 2013, J EUR ACAD DERMATOL, V27, P1172, DOI 10.1111/j.1468-3083.2012.04501.x
   LANGEMANN H, 1992, EUR NEUROL, V32, P248, DOI 10.1159/000116835
   Lapaquette P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/398483
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Le Poole I C, 1993, Exp Dermatol, V2, P145
   LePoole IC, 1996, AM J PATHOL, V148, P1219
   Lerner AG, 2012, CELL METAB, V16, P250, DOI 10.1016/j.cmet.2012.07.007
   Levandowski CB, 2013, P NATL ACAD SCI USA, V110, P2952, DOI 10.1073/pnas.1222808110
   LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018
   Liu M, 2015, MOL ASPECTS MED, V42, P3, DOI 10.1016/j.mam.2014.12.001
   Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9
   Lund BT, 2006, J NEUROL SCI, V249, P122, DOI 10.1016/j.jns.2006.05.066
   Luo YQ, 2014, INT J MOL SCI, V15, P12895, DOI 10.3390/ijms150712895
   Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Maresca V, 1997, J INVEST DERMATOL, V109, P310, DOI 10.1111/1523-1747.ep12335801
   Marhfour I, 2012, DIABETOLOGIA, V55, P2417, DOI 10.1007/s00125-012-2604-3
   Marie J, 2014, BRIT J DERMATOL, V170, P816, DOI 10.1111/bjd.12691
   Martinon F, 2011, CURR OPIN IMMUNOL, V23, P35, DOI 10.1016/j.coi.2010.10.016
   McMahon JM, 2012, MULT SCLER J, V18, P1437, DOI 10.1177/1352458512438455
   MEDRANO EE, 1990, J INVEST DERMATOL, V95, P441
   Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x
   Millington GWM, 2007, INT J DERMATOL, V46, P990, DOI 10.1111/j.1365-4632.2007.03195.x
   Moretti S, 2002, PIGM CELL RES, V15, P87, DOI 10.1034/j.1600-0749.2002.1o049.x
   Morohoshi K, 2011, DISCOV MED, V12, P505
   Morran MP, 2015, MOL ASPECTS MED, V42, P42, DOI 10.1016/j.mam.2014.12.004
   Mosenson JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005127
   MOSHER DB, 1977, BRIT J DERMATOL, V97, P669, DOI 10.1111/j.1365-2133.1977.tb14275.x
   Muralidharan S, 2013, J LEUKOCYTE BIOL, V94, P1167, DOI 10.1189/jlb.0313153
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   NAUGHTON GK, 1983, J EXP MED, V158, P246, DOI 10.1084/jem.158.1.246
   Neumeister P, 2000, LANCET, V355, P1334, DOI 10.1016/S0140-6736(00)02120-6
   Nielsen OH, 2013, NEW ENGL J MED, V369, P754, DOI 10.1056/NEJMct1209614
   NORRIS DA, 1988, J INVEST DERMATOL, V90, P783, DOI 10.1111/1523-1747.ep12461505
   Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649
   Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   OLIVER E. A., 1939, Journal of the American Medical Association, V113, P927
   Oslowski CM, 2012, CELL METAB, V16, P265, DOI 10.1016/j.cmet.2012.07.005
   Ostankovitch M, 2005, J IMMUNOL, V174, P2544, DOI 10.4049/jimmunol.174.5.2544
   Padgett LE, 2013, ANN NY ACAD SCI, V1281, P16, DOI 10.1111/j.1749-6632.2012.06826.x
   PANITCH HS, 1987, LANCET, V1, P893
   Piganelli JD, 2002, DIABETES, V51, P347, DOI 10.2337/diabetes.51.2.347
   PURI N, 1989, ARCH DERMATOL RES, V281, P178, DOI 10.1007/BF00456389
   PURI N, 1987, J INVEST DERMATOL, V88, P434, DOI 10.1111/1523-1747.ep12469795
   Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811
   Reinisch W, 2010, INFLAMM BOWEL DIS, V16, P233, DOI 10.1002/ibd.21038
   RETORNAZ G, 1976, BRIT J DERMATOL, V95, P173, DOI 10.1111/j.1365-2133.1976.tb00822.x
   Richmond JM, 2013, CURR OPIN IMMUNOL, V25, P676, DOI 10.1016/j.coi.2013.10.010
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rivas A, 2015, EXPERT OPIN THER TAR, V19, P1203, DOI 10.1517/14728222.2015.1053869
   Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666.x, 10.1111/j.1600-0625.2007.00666_1.x]
   Schallreuter KU, 2008, EXP DERMATOL, V17, P141, DOI 10.1111/j.1600-0625.2007.00666_2.x
   SCHALLREUTER KU, 1991, J INVEST DERMATOL, V97, P1081, DOI 10.1111/1523-1747.ep12492612
   Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189
   Scheuner D, 2008, ENDOCR REV, V29, P317, DOI 10.1210/er.2007-0039
   Shalbaf M, 2008, EXP DERMATOL, V17, P761, DOI 10.1111/j.1600-0625.2008.00697.x
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Singh Suman, 2012, Indian J Dermatol, V57, P12, DOI 10.4103/0019-5154.92668
   Skowera A, 2008, J CLIN INVEST, V118, P3390, DOI 10.1172/JCI35449
   Sloane JA, 2010, P NATL ACAD SCI USA, V107, P11555, DOI 10.1073/pnas.1006496107
   Spritz RA, 2013, J DERMATOL, V40, P310, DOI 10.1111/1346-8138.12147
   Spritz RA, 2012, J INVEST DERMATOL, V132, P268, DOI 10.1038/jid.2011.321
   Sun JH, 2015, MOL ASPECTS MED, V42, P105, DOI 10.1016/j.mam.2015.01.001
   Taieb A, 2009, NEW ENGL J MED, V360, P160, DOI 10.1056/NEJMcp0804388
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Toosi S, 2012, J INVEST DERMATOL, V132, P2601, DOI 10.1038/jid.2012.181
   Tu CX, 2003, J DERMATOL SCI, V31, P73, DOI 10.1016/S0923-1811(02)00151-2
   Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46
   Valatas V, 2015, EUR J PHARMACOL, V759, P253, DOI 10.1016/j.ejphar.2015.03.017
   van den Boorn JG, 2011, J INVEST DERMATOL, V131, P1240, DOI 10.1038/jid.2011.16
   van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32
   van den Wijngaard R, 2000, LAB INVEST, V80, P1299, DOI 10.1038/labinvest.3780138
   Wankowicz-Kalinska A, 2003, LAB INVEST, V83, P683, DOI 10.1097/01.LAB.0000069521.42488.1B
   Weetman AP, 2012, EUR THYROID J, V1, P243, DOI 10.1159/000343834
   Willcox A, 2009, CLIN EXP IMMUNOL, V155, P173, DOI 10.1111/j.1365-2249.2008.03860.x
   Wlodarska M, 2015, CELL HOST MICROBE, V17, P577, DOI 10.1016/j.chom.2015.04.008
   Wu SW, 2015, PIGM CELL MELANOMA R, V28, P744, DOI 10.1111/pcmr.12402
   Yu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051040
   Zhong JX, 2012, EXP DIABETES RES, DOI 10.1155/2012/238980
   Zhong Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00333
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
   Zhu H, 2012, EXP BIOL MED, V237, P474, DOI 10.1258/ebm.2011.011358
NR 152
TC 29
Z9 29
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-2896
EI 1600-065X
J9 IMMUNOL REV
JI Immunol. Rev.
PD JAN
PY 2016
VL 269
IS 1
SI SI
BP 11
EP 25
DI 10.1111/imr.12369
PG 15
WC Immunology
SC Immunology
GA CZ2EA
UT WOS:000366916700003
PM 26683142
OA Green Accepted
DA 2020-07-08
ER

PT J
AU Silverberg, JI
   Silverberg, NB
AF Silverberg, Jonathan I.
   Silverberg, Nanette B.
TI Vitiligo Disease Triggers: Psychological Stressors Preceding the Onset
   of Disease
SO CUTIS
LA English
DT Article
ID OF-LIFE IMPAIRMENT; SERUM HOMOCYSTEINE; FOLIC-ACID; PATHOGENESIS;
   PSORIASIS; EVENTS; CELLS; ASSOCIATION; CYTOKINES; VULGARIS
AB Vitiligo is the loss of skin pigmentation caused by autoimmune destruction of melanocytes. Little is known about the impact of psychological stressors preceding vitiligo onset on symptoms associated with vitiligo and the extent of disease. We performed a questionnaire-based study of 1541 adults with vitiligo to evaluate the impact of psychological stressors in this patient population. Psychological stressors should be considered as potential disease triggers in vitiligo patients, and screening of vitiligo patients for psychological stressors and associated symptoms should be included in routine assessment.
C1 [Silverberg, Jonathan I.] Northwestern Univ, Dept Dermatol, Dept Preventat Med, Chicago, IL 60611 USA.
   [Silverberg, Jonathan I.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA.
   [Silverberg, Nanette B.] Icahn Sch Med Mt Sinai, Mt Sinai St Lukes Roosevelt & Beth Israel Med Ctr, New York, NY 10029 USA.
RP Silverberg, NB (corresponding author), Dept Dermatol, 1090 Amsterdam Ave,Ste 11D, New York, NY 10025 USA.
EM nsilverb@chpnet.org
OI Silverberg, Jonathan/0000-0003-3686-7805
CR ALABADIE MSK, 1994, BRIT J DERMATOL, V131, P160
   Balci DD, 2009, EUR J DERMATOL, V19, P382, DOI 10.1684/ejd.2009.0671
   Barisic-Drusko V, 2004, COLLEGIUM ANTROPOL, V28, P277
   Basak PY, 2009, J AM ACAD DERMATOL, V60, P256, DOI 10.1016/j.jaad.2008.09.048
   Birol A, 2006, INT J DERMATOL, V45, P992, DOI 10.1111/j.1365-4632.2006.02744.x
   Cakmak SK, 2009, J EUR ACAD DERMATOL, V23, P300, DOI 10.1111/j.1468-3083.2008.03024.x
   GORONZY J, 1985, CLIN EXP IMMUNOL, V61, P593
   Grimes PE, 2004, J AM ACAD DERMATOL, V51, P52, DOI 10.1016/j.jaad.2003.12.031
   Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S
   Jonasson T, 2005, CLIN CHEM LAB MED, V43, P628, DOI 10.1515/CCLM.2005.108
   Kanwar AJ, 2013, J CUTAN MED SURG, V17, P253, DOI 10.2310/7750.2013.12075
   Kemp EH, 2011, EXP DERMATOL, V20, P35, DOI 10.1111/j.1600-0625.2010.01181.x
   Malerba M, 2006, BRIT J DERMATOL, V155, P1165, DOI 10.1111/j.1365-2133.2006.07503.x
   Manolache L, 2009, J EUR ACAD DERMATOL, V23, P187, DOI 10.1111/j.1468-3083.2008.02764.x
   Manolache L, 2007, J EUR ACAD DERMATOL, V21, P921, DOI 10.1111/j.1468-3083.2006.02106.x
   Moretti S, 2002, PIGM CELL RES, V15, P87, DOI 10.1034/j.1600-0749.2002.1o049.x
   Ongenae K, 2003, PIGM CELL RES, V16, P90, DOI 10.1034/j.1600-0749.2003.00023.x
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Picardi A, 2003, PSYCHOTHER PSYCHOSOM, V72, P150, DOI 10.1159/000069731
   SALZER BA, 1995, DERMATOLOGY, V190, P109, DOI 10.1159/000246657
   Shaker OG, 2008, BRIT J DERMATOL, V159, P720, DOI 10.1111/j.1365-2133.2008.08712.x
   Shastry S, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-27
   Silverberg JI, 2014, PEDIATR DERMATOL, V31, P309, DOI 10.1111/pde.12226
   Silverberg JI, 2013, JAMA DERMATOL, V149, P159, DOI 10.1001/jamadermatol.2013.927
   Silverberg JI, 2011, J AM ACAD DERMATOL, V64, P445, DOI 10.1016/j.jaad.2010.08.025
   Silverberg JI, 2010, J AM ACAD DERMATOL, V62, P937, DOI 10.1016/j.jaad.2009.11.024
   Zailaie MZ, 2005, SAUDI MED J, V26, P799
NR 27
TC 12
Z9 14
U1 0
U2 4
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 0011-4162
EI 2326-6929
J9 CUTIS
JI Cutis
PD MAY
PY 2015
VL 95
IS 5
BP 255
EP 262
PG 8
WC Dermatology
SC Dermatology
GA CI6ZW
UT WOS:000354913700002
PM 26057504
DA 2020-07-08
ER

PT J
AU Setaluri, V
AF Setaluri, Vijayasaradhi
TI Autophagy as a Melanocytic Self-Defense Mechanism
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Editorial Material
AB Defects in autophagy have implications for melanocyte survival and manifestations of skin pigmentary disorders. Zhang et al (2015) show that mouse melanocytes lacking the autophagy protein Atg7 undergo premature senescence in vitro and accumulate products of oxidative damage, despite activation of the redox response. Interestingly, contrary to previous findings, the melanocyte-specific deficiency in autophagy did not cause major defects in melanosome biogenesis, nor did it produce visually striking changes in mouse coat color.
C1 [Setaluri, Vijayasaradhi] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.
RP Setaluri, V (corresponding author), Univ Wisconsin, Dept Dermatol, MSC, Room 439,1300 Univ Ave, Madison, WI 53706 USA.
EM vsetaluri@dermatology.wisc.edu
FU NIAMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R21 AR062734, P30 AR066524,
   1P30AR066524, R21AR062734]; BLRD VA [I01 BX002623]
CR Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Ganesan AK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000298
   HIRONE T, 1978, ACTA DERM-VENEREOL, V58, P223
   Kalie E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075313
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Sitaram A, 2012, PHYSIOLOGY, V27, P85, DOI 10.1152/physiol.00043.2011
   Smith JW, 2005, PIGM CELL RES, V18, P417, DOI 10.1111/j.1600-0749.2005.00265.x
   Zhang CF, 2015, J INVEST DERMATOL, V135, P1348, DOI 10.1038/jid.2014.439
NR 9
TC 4
Z9 5
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2015
VL 135
IS 5
BP 1215
EP 1217
DI 10.1038/jid.2015.19
PG 3
WC Dermatology
SC Dermatology
GA CG1CQ
UT WOS:000353011000005
PM 25882462
OA Green Accepted, Bronze
DA 2020-07-08
ER

PT J
AU Noh, S
   Kim, M
   Park, CO
   Hann, SK
   Oh, SH
AF Noh, Seongmin
   Kim, Miri
   Park, Chang Ook
   Hann, Seung-Kyung
   Oh, Sang Ho
TI Comparison of the Psychological Impacts of Asymptomatic and Symptomatic
   Cutaneous Diseases: Vitiligo and Atopic Dermatitis
SO ANNALS OF DERMATOLOGY
LA English
DT Article
DE Atopic dermatitis; Psychological impacts; Vitiligo
ID QUALITY-OF-LIFE; PSYCHIATRIC MORBIDITY; TRAIT-ANXIETY; DEPRESSION;
   PSORIASIS; INDEX; INVENTORY; EXPERIENCE; CAMOUFLAGE; RISK
AB Background: Vitiligo and atopic dermatitis (AD) are common dermatological disorders which may cause significant psychological and social distress leading to impaired quality of life (QoL) in patients. Objective: We evaluated the degree of psychological stress and impairment of QoL in vitiligo patients as compared with AD patients and normal controls (NCs). Methods: A total of 60 patients from each group and 60 NCs were enrolled. Five questionnaires on depression (Beck depression inventory, BDI), state anxiety (SA) and trait anxiety (TA), interaction anxiousness (IAS), private body consciousness (PBC) and dermatologic QoL were used. Results: The vitiligo patients had a significantly higher level of TA (p < 0.01), PBC (p < 0.001) and impaired QoL (p< 0.001) than NCs, but not BDI, SA and IAS. The AD patients had significantly higher scores for all five questionnaire items compared with NCs. In the comparison between the AD and vitiligo groups, all of the indexes except body consciousness were higher in AD patients than in vitiligo patients: BDI (p< 0.01), SA (p < 0.05), TA (p< 0.001), IAS (p< 0.01) and impaired QoL (p < 0.001). Exposure of vitiligo lesions was not a significant variable in the analysis of the contribution of clinical variables of vitiligo on psychological stress and QoL. Conclusion: Vitiligo, which is not accompanied by any symptoms, involves less psychological impact than AD, which is accompanied by itching. Compared to NCs, however, the elevated general anxiety and body consciousness in patients with vitiligo suggests that they may be more concerned with the aggravation of hypopigmented patches than difficulties in social interactions.
C1 [Noh, Seongmin; Kim, Miri; Park, Chang Ook; Oh, Sang Ho] Yonsei Univ, Coll Med, Dept Dermatol, Seoul 120752, South Korea.
   [Noh, Seongmin; Kim, Miri; Park, Chang Ook; Oh, Sang Ho] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Seoul 120752, South Korea.
   [Hann, Seung-Kyung] Korea Inst Vitiligo Res, Seoul, South Korea.
   [Hann, Seung-Kyung] Drs Woo & Hanns Skin Ctr, Seoul, South Korea.
RP Oh, SH (corresponding author), Yonsei Univ, Coll Med, Dept Dermatol, 50 Yonsei Ro, Seoul 120752, South Korea.
EM oddung93@yuhs.ac
OI Park, Chang Ook/0000-0003-3856-1201; Oh, Sang Ho/0000-0002-4477-1400
CR Arima M, 2005, J DERMATOL, V32, P160, DOI 10.1111/j.1346-8138.2005.tb00738.x
   Bae BG, 2012, ACTA DERM-VENEREOL, V92, P57, DOI 10.2340/00015555-1189
   Basra MKA, 2008, BRIT J DERMATOL, V159, P997, DOI 10.1111/j.1365-2133.2008.08832.x
   Belhadjali H, 2007, ANN DERMATOL VENER, V134, P233, DOI 10.1016/S0151-9638(07)91814-1
   Bilgic O, 2011, CLIN EXP DERMATOL, V36, P360, DOI 10.1111/j.1365-2230.2010.03965.x
   Carney CE, 2009, J PSYCHIATR RES, V43, P576, DOI 10.1016/j.jpsychires.2008.09.002
   Choi S, 2010, J EUR ACAD DERMATOL, V24, P524, DOI 10.1111/j.1468-3083.2009.03452.x
   Chu SY, 2012, BRIT J DERMATOL, V166, P525, DOI 10.1111/j.1365-2133.2011.10714.x
   DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101
   FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x
   Grob JJ, 2005, BRIT J DERMATOL, V152, P289, DOI 10.1111/j.1365-2133.2005.06385.x
   Hahn D, 1996, KOREAN J HLTH PSYCHO, V1, P1, DOI DOI 10.4069/kjwhn.2011.17.5.439
   Hahn H. M., 1986, J KOREAN NEUROPSYCHI, V25, P487
   HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44
   Hashiro M, 1997, J DERMATOL SCI, V14, P63, DOI 10.1016/S0923-1811(96)00553-1
   Hashizume H, 2006, CURR OPIN ALLERGY CL, V6, P335, DOI 10.1097/01.all.0000244793.03239.40
   Homan MWL, 2009, J AM ACAD DERMATOL, V61, P411, DOI 10.1016/j.jaad.2009.03.022
   Kent G, 1996, J AM ACAD DERMATOL, V35, P895, DOI 10.1016/S0190-9622(96)90112-7
   Kent G, 1996, CLIN EXP DERMATOL, V21, P330
   Kim DY, 2009, J DERMATOL, V36, P317, DOI 10.1111/j.1346-8138.2009.00646.x
   Kostopoulou P, 2009, BRIT J DERMATOL, V161, P128, DOI 10.1111/j.1365-2133.2009.09077.x
   LEARY MR, 1983, J PERS ASSESS, V47, P66, DOI 10.1207/s15327752jpa4701_8
   Mattoo SK, 2001, J DERMATOL, V28, P424, DOI 10.1111/j.1346-8138.2001.tb00004.x
   MCCLEARY R, 1991, PSYCHOL REP, V68, P1075, DOI 10.2466/PR0.68.4.1075-1078
   MILLER LC, 1981, J PERS SOC PSYCHOL, V41, P397, DOI 10.1037/0022-3514.41.2.397
   Misery L, 2007, DERMATOLOGY, V215, P123, DOI 10.1159/000104263
   NAKAZATO K, 1989, PERCEPT MOTOR SKILL, V69, P611, DOI 10.2466/pms.1989.69.2.611
   Oh SH, 2010, ACTA DERM-VENEREOL, V90, P582, DOI 10.2340/00015555-0933
   Ongenae K, 2005, BRIT J DERMATOL, V152, P1165, DOI 10.1111/j.1365-2133.2005.06456.x
   Ongenae K, 2005, DERMATOLOGY, V210, P279, DOI 10.1159/000084751
   Parsad D, 2003, BRIT J DERMATOL, V148, P373, DOI 10.1046/j.1365-2133.2003.05097_9.x
   Parsad Davinder, 2003, Health Qual Life Outcomes, V1, P58, DOI 10.1186/1477-7525-1-58
   Picardi A, 2001, ACTA DERM-VENEREOL, V81, P410
   Poole H, 2006, CLIN J PAIN, V22, P790, DOI 10.1097/01.ajp.0000210930.20322.93
   PORTER JR, 1986, J AM ACAD DERMATOL, V15, P220, DOI 10.1016/S0190-9622(86)70160-6
   PORTER JR, 1990, J AM ACAD DERMATOL, V22, P221, DOI 10.1016/0190-9622(90)70028-G
   Sampogna F, 2008, BRIT J DERMATOL, V159, P351, DOI 10.1111/j.1365-2133.2008.08678.x
   Schmid-Ott G, 2007, J EUR ACAD DERMATOL, V21, P456, DOI 10.1111/j.1468-3083.2006.01897.x
   Sharma N, 2001, J DERMATOL, V28, P419, DOI 10.1111/j.1346-8138.2001.tb00003.x
   Stewart SH, 1997, J ANXIETY DISORD, V11, P179, DOI 10.1016/S0887-6185(97)00005-4
   Tanioka M, 2010, J COSMET DERMATOL-US, V9, P72, DOI 10.1111/j.1473-2165.2010.00479.x
   Wang KY, 2011, J EUR ACAD DERMATOL, V25, P429, DOI 10.1111/j.1468-3083.2010.03808.x
   Wu WH, 2010, J ALLERGY CLIN IMMUN, V126, P290, DOI 10.1016/j.jaci.2010.05.024
NR 43
TC 15
Z9 17
U1 0
U2 6
PU KOREAN DERMATOLOGICAL ASSOC
PI SEOUL
PA 305 SEOCHO NASAN, SUITE OFFICE 1330-16, SEOCHO-2-DONG, SEOCHO-GU, SEOUL,
   137-858, SOUTH KOREA
SN 1013-9087
J9 ANN DERMATOL
JI Ann. Dermatol.
PD NOV
PY 2013
VL 25
IS 4
BP 454
EP 461
DI 10.5021/ad.2013.25.4.454
PG 8
WC Dermatology
SC Dermatology
GA 280DM
UT WOS:000329008900010
PM 24371393
OA Green Published, Other Gold
DA 2020-07-08
ER

PT J
AU Lugovic-Mihic, L
   Ljubesic, L
   Mihic, J
   Vukovic-Cvetkovic, V
   Troskot, N
   Situm, M
AF Lugovic-Mihic, Liborija
   Ljubesic, Luka
   Mihic, Josip
   Vukovic-Cvetkovic, Vlasta
   Troskot, Nina
   Situm, Mirna
TI PSYCHONEUROIMMUNOLOGIC ASPECTS OF SKIN DISEASES
SO ACTA CLINICA CROATICA
LA English
DT Review
DE Psychoneuroimmunology; Skin; Skin diseases; Interleukins; Neuropeptides;
   Hormones
ID CORTICOTROPIN-RELEASING HORMONE; HUMAN HACAT KERATINOCYTES;
   ATOPIC-DERMATITIS; INTERLEUKIN-18 EXPRESSION; PSYCHOLOGICAL STRESS;
   BETA-ENDORPHIN; PSORIASIS; NEUROENDOCRINE; AXIS; INFLAMMATION
AB As mental and psychological issues are important in the development of many dermatologic diseases, these factors are of special interest in research. Psychoneuroimmunology is the study of interaction between psychological processes and the nervous and immune systems of the human body, and it was comprehensively described for the first time about 30 years ago. Communication between the mind and the skin involves the psycho-immuno-endocrine-cutaneous system, encompassing the activities of the brain, the immune system and the skin, with participation of different neuropeptides, interleukins, and immune system messengers. Many common dermatologic diseases have some form of psychomediated pathogenesis that partially accounts for the development of skin lesions. There is a link between emotional stressors (acute or chronic), psychiatric diseases, and dermatoses (e.g., psoriasis, atopic dermatitis, urticaria, viral warts, herpes simplex, vitiligo, acnes, alopecia, prurigo, etc.) and different cytokines and mediators produced in the skin and involved in their pathogenesis. A prominent role is played by those agents that belong to the hypothalamic-pituitary-adrenal axis.
C1 [Lugovic-Mihic, Liborija; Ljubesic, Luka; Troskot, Nina; Situm, Mirna] Sestre Milosrdnice Univ Hosp Ctr, Clin Dept Dermatovenereol, HR-10000 Zagreb, Croatia.
   [Mihic, Josip] Dr Josip Bencevic Gen Hosp, Div Neurosurg, Slavonski Brod, Croatia.
   [Vukovic-Cvetkovic, Vlasta] Sestre Milosrdnice Univ Hosp Ctr, Clin Dept Neurol, HR-10000 Zagreb, Croatia.
RP Lugovic-Mihic, L (corresponding author), Sestre Milosrdnice Univ Hosp Ctr, Clin Dept Dermatovenereol, Vinogradska C 29, HR-10000 Zagreb, Croatia.
EM liborija@gmail.com
RI Situm, Mirna/S-3206-2018
OI Situm, Mirna/0000-0003-0316-7466; Lugovic-Mihic,
   Liborija/0000-0001-7494-5742
CR Afsar FS, 2010, J CUTAN MED SURG, V14, P13, DOI 10.2310/7750.2010.09021
   Bakula A, 2011, ACTA CLIN CROAT, V50, P553
   Basavaraj K H, 2010, Indian J Psychiatry, V52, P270, DOI 10.4103/0019-5545.70992
   Buske-Kirschbaum A, 2010, BRAIN BEHAV IMMUN, V24, P1347, DOI 10.1016/j.bbi.2010.06.013
   Chida Y, 2009, BRAIN BEHAV IMMUN, V23, P917, DOI 10.1016/j.bbi.2009.04.009
   Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x
   Chung WL, 2012, SINGAP MED J, V53, P789
   Dhabhar FS, 2013, CLIN DERMATOL, V31, P18, DOI 10.1016/j.clindermatol.2011.11.003
   Dou YC, 2006, ARCH DERMATOL RES, V298, P31, DOI 10.1007/s00403-006-0657-1
   Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   Gabrilovac J., 2008, PSIHONEUROIMUNOLOGIJ, P103
   GLINSKI W, 1995, ACTA DERM-VENEREOL, V75, P9
   GUPTA MA, 1988, ARCH DERMATOL, V124, P1052, DOI 10.1001/archderm.124.7.1052
   Karanikas E, 2009, J DERMATOL, V36, P35, DOI 10.1111/j.1346-8138.2008.00583.x
   Katsarou-Katsari A, 1999, INT J IMMUNOPATH PH, V12, P7
   Kiecolt-Glaser JK, 2002, ANNU REV PSYCHOL, V53, P83, DOI 10.1146/annurev.psych.53.100901.135217
   KIM JE, 2012, STRESS HORMONE SKIN
   Kimata H, 2003, EUR J CLIN INVEST, V33, P513, DOI 10.1046/j.1365-2362.2003.01177.x
   Lee CH, 2006, BRIT J DERMATOL, V154, P1100, DOI 10.1111/j.1365-2133.2006.07191.x
   Lee HJ, 2009, EXP DERMATOL, V18, P199, DOI 10.1111/j.1600-0625.2008.00781.x
   Leibovici V, 2010, J EUR ACAD DERMATOL, V24, P897, DOI 10.1111/j.1468-3083.2009.03542.x
   Lugovic L., 2007, Acta Medica Croatica, V61, P383
   MOLDOFSKY H, 1989, FASEB J, V3, P1972
   O'Kane M, 2006, EXP DERMATOL, V15, P143
   Oh SH, 2010, ACTA DERM-VENEREOL, V90, P582, DOI 10.2340/00015555-0933
   Orion E, 2012, CLIN DERMATOL, V30, P280, DOI 10.1016/j.clindermatol.2011.08.014
   Park HJ, 2005, J INVEST DERMATOL, V124, P751, DOI 10.1111/j.0022-202X.2005.23656.x
   Park HJ, 2007, J INVEST DERMATOL, V127, P1210, DOI 10.1038/sj.jid.5700703
   Pisarchik A, 2004, EUR J BIOCHEM, V271, P2821, DOI 10.1111/j.1432-1033.2004.04216.x
   Schmid-Ott G, 2009, BRIT J DERMATOL, V160, P782, DOI 10.1111/j.1365-2133.2008.09013.x
   Schut C, 2013, ACTA DERM-VENEREOL, V93, P57, DOI 10.2340/00015555-1415
   Schwartz R, 2009, REV MED CHILE, V137, P53, DOI [/S0034-98872009000100008, 10.4067/S0034-98872009000100008]
   Segerstrom SC, 2000, ANN BEHAV MED, V22, P180, DOI 10.1007/BF02895112
   Slominski A, 2000, PHYSIOL REV, V80, P979
   Slominski A, 2006, J CELL PHYSIOL, V206, P780, DOI 10.1002/jcp.20530
   Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012
   Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014
   Urpe M, 2005, DERMATOL CLIN, V23, P609, DOI 10.1016/j.det.2005.05.017
   Verhoeven EWM, 2009, J INVEST DERMATOL, V129, P2075, DOI 10.1038/jid.2008.460
   Vidrih B, 2012, ACTA CLIN CROAT, V51, P403
   Zhang XQ, 2005, EXP BIOL MED, V230, P376, DOI 10.1177/15353702-0323006-05
NR 42
TC 16
Z9 18
U1 0
U2 9
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD SEP
PY 2013
VL 52
IS 3
BP 337
EP 345
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 287JV
UT WOS:000329539000009
PM 24558766
OA DOAJ Gold
DA 2020-07-08
ER

PT J
AU Passeron, T
   Ortonne, JP
AF Passeron, Thierry
   Ortonne, Jean-Paul
TI Activation of the Unfolded Protein Response in Vitiligo: The Missing
   Link?
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Editorial Material
ID DEPIGMENTING AGENT; MELANOCYTES; EPIDERMIS; ACCUMULATION; DYSFUNCTION;
   MECHANISMS; GENERATION; CELLS
AB Vitiligo is characterized by a substantial loss of functional melanocytes in the epidermis and sometimes in hair follicles. Genetic and pathophysiological studies have provided strong evidence that vitiligo is a polygenetic, multifactorial disorder. The key roles of oxidative stress within melanocytes and anti-melanocyte immune responses have been addressed in many studies, but the relationship between these mechanisms remains unclear. In this issue, Toosi et al. report the upregulation of IL-6 and IL-8 after the activation of the unfolded protein response (UPR) following exposure of melanocytes to phenols. Their results shed light on the missing link between oxidative stress and immune responses in vitiligo.
C1 [Passeron, Thierry; Ortonne, Jean-Paul] Univ Hosp Nice, Dept Dermatol, Nice, France.
   [Passeron, Thierry] INSERM U1065 Team 12, Nice, France.
RP Passeron, T (corresponding author), CHU Nice, Archet Hosp 2, Dept Dermatol, 151 Route St Antoine de Ginestiere, F-06200 Nice, France.
EM passeron@unice.fr
OI Passeron, Thierry/0000-0002-0797-6570
CR Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x
   BOISSY RE, 1991, J INVEST DERMATOL, V97, P395, DOI 10.1111/1523-1747.ep12480976
   Dell'Anna ML, 2006, PIGM CELL RES, V19, P406, DOI 10.1111/j.1600-0749.2006.00333.x
   Dell'Anna ML, 2010, J CELL PHYSIOL, V223, P187, DOI 10.1002/jcp.22027
   Goodman WA, 2009, J IMMUNOL, V183, P3170, DOI 10.4049/jimmunol.0803721
   Grimes PE, 2004, J AM ACAD DERMATOL, V51, P52, DOI 10.1016/j.jaad.2003.12.031
   Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463
   Hoffmann A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031298
   Jin Y, 2012, J INVEST DERMATOL, V132, P1730, DOI 10.1038/jid.2012.37
   Kitamura R, 2004, J PATHOL, V202, P463, DOI 10.1002/path.1538
   Klarquist J, 2010, PIGM CELL MELANOMA R, V23, P276, DOI 10.1111/j.1755-148X.2010.00688.x
   Kotobuki Y, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00945.x
   Kroll TM, 2005, J INVEST DERMATOL, V124, P798, DOI 10.1111/j.0022-202X.2005.23653.x
   Lan CCE, 2009, BRIT J DERMATOL, V160, P1180, DOI 10.1111/j.1365-2133.2009.09064.x
   Legros L, 2005, BRIT J DERMATOL, V153, P691, DOI 10.1111/j.1365-2133.2005.06813.x
   Moretti S, 2009, HISTOL HISTOPATHOL, V24, P849, DOI 10.14670/HH-24.849
   Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189
   Spritz RA, 2012, J INVEST DERMATOL, V132, P268, DOI 10.1038/jid.2011.321
   Taher ZA, 2009, BRIT J DERMATOL, V161, P654, DOI 10.1111/j.1365-2133.2009.09217.x
   Toosi S, 2012, J INVEST DERMATOL, V132, P2601, DOI 10.1038/jid.2012.181
   van den Boorn JG, 2011, J INVEST DERMATOL, V131, P1240, DOI 10.1038/jid.2011.16
   Wang CQF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018907
NR 22
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD NOV
PY 2012
VL 132
IS 11
BP 2502
EP 2504
DI 10.1038/jid.2012.328
PG 3
WC Dermatology
SC Dermatology
GA 022XJ
UT WOS:000309997200007
PM 23069909
OA Bronze
DA 2020-07-08
ER

PT J
AU Schwartz, R
   Sepulveda, JE
   Quintana, T
AF Schwartz, Rodrigo
   Enrique Sepulveda, Juan
   Quintana, Teresa
TI Possible role of psychological and environmental factors in the genesis
   of chilhood vitiligo
SO REVISTA MEDICA DE CHILE
LA Spanish
DT Article
DE Child, psychology; Temperament; Vitiligo
ID GENERALIZED ANXIETY DISORDER; ACUTE MENTAL STRESS; QUALITY-OF-LIFE;
   CHARACTER INVENTORY; PLASMA-CATECHOLAMINE; TEMPERAMENT; PERSONALITY;
   EVENTS; INTERLEUKIN-6; BIOSYNTHESIS
AB Background: The exposue to stressing ituations may play a role in the appearance of vitiligo. Patients with the disease have a greater sensitivity to environmental stress temperament and character of patients with vitiligo and explore the relationship of the disease with negative life events and life quality impairment. Material and methods: The study population were 21 patients with vitiligo aged 5 to 12 years, and two control groups (G1 and G2), G1 was composed by 14 healthy siblings of vitiligo patients. G2 was composed by 21 age and gender matched healthy students from two schools in Santiago, Chile. The Junior Temperament and Character Inventory (JTCI), the Qualitative Psychosocial Development Survey (QPDS), the Life Event Checklist (LEC) and the Childrens' Life Quality Index (CDLQI) were applied (LEC only to vitiligo patients). Results: On the temperament dimensions, vitiligo patients scored high on the " harm avoidance" scale in comparison to G2 (13.7 v/s 10.6). Compared with G1, QPDS showed in vitiligo patients a higher frequency of fear to strangers (71% and 36%. respectively) and a predominant feeling of fear and shyness in response to changes in a close relative (80% and 8%, respectively). There was a negative correlation (protective factor) between the character dimension " self-directedness" and CDLQI score (r = -0.703). Conclusions: In this group of patients, we found a possible relationship between a specific tempaerament dimension, vitiligo and its impact on life quality (Rev Med Chile 2009; 137: 53-62).
C1 [Schwartz, Rodrigo] Dept Dermatol, Clin Las Condes, Las Condes, Chile.
   [Schwartz, Rodrigo] Univ Chile, Serv Dermatol, Hosp Clin, Santiago, Chile.
   [Enrique Sepulveda, Juan] Univ Chile, Clin Psiquiatr Univ, Santiago, Chile.
   [Quintana, Teresa] Univ Adolfo Ibanez, Santiago, Chile.
RP Schwartz, R (corresponding author), Lo Fontecilla 441, Las Condes, Fonos, Chile.
EM Schwartz.rodrigo@gmail.com
CR AKERSTEDT T, 1983, ACTA PHYSIOL SCAND, V117, P19, DOI 10.1111/j.1748-1716.1983.tb07174.x
   Anderberg UM, 1999, NORD J PSYCHIAT, V53, P353, DOI 10.1080/080394899427827
   Bell IR, 1997, BEHAV MED, V22, P168, DOI 10.1080/08964289.1997.10543550
   Boz C, 2004, PSYCHIAT CLIN NEUROS, V58, P536, DOI 10.1111/j.1440-1819.2004.01297.x
   Castilla-Cortazar I, 1998, J PHYSIOL BIOCHEM, V54, P203
   Cloninger CR, 1999, AUST NZ J PSYCHIAT, V33, P174, DOI 10.1046/j.1440-1614.1999.00533.x
   CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008
   CLONINGER R, 1998, J AFFECT DISORDERS, P21
   Cucchi ML, 2000, PIGM CELL RES, V13, P28, DOI 10.1034/j.1600-0749.2000.130106.x
   De Tiedra AG, 1998, ACTA DERMOSIFILIOGR, V89, P692
   DUNERVA SG, 1973, VESTN DERMATOL VENER, V10, P33
   Gothelf D, 2004, COMPR PSYCHIAT, V45, P192, DOI 10.1016/j.comppsych.2004.02.010
   Hosak L, 2004, EUR PSYCHIAT, V19, P193, DOI 10.1016/j.eurpsy.2004.04.003
   HOWITZ J, 1977, ARCH DERMATOL, V113, P47, DOI 10.1001/archderm.113.1.47
   Jiang N, 2003, J PSYCHOSOM RES, V55, P493, DOI 10.1016/S0022-3999(03)00021-7
   JOHNSON JH, 1980, STRESS ANXIETY HEMIS
   KAGAN J, 1987, CHILD DEV, V58, P1459, DOI 10.1111/j.1467-8624.1987.tb03858.x
   Kagan J, 1998, CHILD DEV, V69, P1483, DOI 10.2307/1132126
   KAGAN J, 1988, SCIENCE, V240, P167, DOI 10.1126/science.3353713
   LERNER AB, 1959, J INVEST DERMATOL, V32, P285, DOI 10.1038/jid.1959.49
   LERNER AB, 1971, AM J MED, V51, P141, DOI 10.1016/0002-9343(71)90232-4
   LEWISJONES MS, 1995, BRIT J DERMATOL, V132, P942
   Luby JL, 1999, PSYCHOL REP, V84, P1127, DOI 10.2466/PR0.84.3.1127-1138
   MEHTA NR, 1973, INDIAN J MED RES, V61, P145
   Moretti S, 2002, PIGM CELL RES, V15, P87, DOI 10.1034/j.1600-0749.2002.1o049.x
   MORRONE A, 1992, PIGM CELL RES, V5, P65, DOI 10.1111/j.1600-0749.1992.tb00003.x
   NESSE RM, 1984, ARCH GEN PSYCHIAT, V41, P771
   Ongenae K, 2005, BRIT J DERMATOL, V152, P1165, DOI 10.1111/j.1365-2133.2005.06456.x
   Ongenae K, 2005, DERMATOLOGY, V210, P279, DOI 10.1159/000084751
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Parsad D, 2003, BRIT J DERMATOL, V148, P373, DOI 10.1046/j.1365-2133.2003.05097_9.x
   PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0
   Picardi A, 2003, PSYCHOTHER PSYCHOSOM, V72, P150, DOI 10.1159/000069731
   SALZER BA, 1995, DERMATOLOGY, V190, P109, DOI 10.1159/000246657
   SCHALLREUTER KU, 1994, BBA-MOL BASIS DIS, V1226, P181, DOI 10.1016/0925-4439(94)90027-2
   Schwartz CE, 1996, J ANXIETY DISORD, V10, P89, DOI 10.1016/0887-6185(96)87623-7
   Schwartz CE, 2003, SCIENCE, V300, P1952, DOI 10.1126/science.1083703
   SEVY S, 1989, BIOL PSYCHIAT, V25, P141, DOI 10.1016/0006-3223(89)90158-3
   Starcevic V, 1996, J AFFECT DISORDERS, V37, P75, DOI 10.1016/0165-0327(95)00058-5
   Steptoe A, 2001, CLIN SCI, V101, P185, DOI 10.1042/CS20010038
   Tu CX, 2003, J DERMATOL SCI, V31, P73, DOI 10.1016/S0923-1811(02)00151-2
   von Kanel R, 2006, BRAIN BEHAV IMMUN, V20, P40, DOI 10.1016/j.bbi.2005.03.013
NR 42
TC 17
Z9 18
U1 0
U2 5
PU SOC MEDICA SANTIAGO
PI SANTIAGO 9
PA BERNARDA MORIN 488 PROVIDENCIA, CASILLA 168 CORREO 55, SANTIAGO 9,
   00000, CHILE
SN 0034-9887
J9 REV MED CHILE
JI Rev. Medica Chile
PD JAN
PY 2009
VL 137
IS 1
BP 53
EP 62
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 415ZS
UT WOS:000263975600008
PM 19399322
DA 2020-07-08
ER

PT J
AU Denman, CJ
   McCracken, J
   Hariharan, V
   Klarquist, J
   Oyarbide-Valencia, K
   Guevara-Patino, JA
   Le Poole, IC
AF Denman, Cecele J.
   McCracken, James
   Hariharan, Vidhya
   Klarquist, Jared
   Oyarbide-Valencia, Kepa
   Guevara-Patino, Jose A.
   Le Poole, I. Caroline
TI HSP70i accelerates depigmentation in a mouse model of autoimmune
   vitiligo
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID TYROSINASE-RELATED PROTEIN-2; HUMAN MELANOCYTES; IMMUNE-RESPONSE;
   TUMOR-IMMUNITY; GENE GUN; HEAT-SHOCK-PROTEIN-70; CELLS; VACCINATION;
   EXPRESSION; MELANOMA
AB Vitiligo is a T-cell-mediated autoimmune disease of the skin. Progressive depigmentation accelerates in response to stress. Personal trauma, contact with bleaching phenols, overexposure to UV, and mechanical injury can lead to progressive loss of melanocytes. This study was focused on the role of stress protein heat shock protein (HSP)70 for translating stress into an autoimmune disease to melanocytes. Intracellular HSP70 can act as a cytoprotectant, preventing apoptosis in cells under stress. Isoform HSP70i can be secreted by live cells, and in prior in vitro studies, HSP70 has been shown to activate dendritic cells and elicit an immune response to chaperoned proteins and peptides. Here, the role of HSP70 in precipitating and perpetuating vitiligo was assessed in vivo in a mouse model of autoimmune vitiligo. In this model, depigmentation was introduced by gene gun vaccination with eukaryotic expression plasmids encoding melanocyte differentiation antigens. Inclusion of human and mouse-derived inducible HSP70 in the vaccination protocol significantly increased and accelerated depigmentation in this model, accompanied by the induction of prolonged humoral responses to HSP70. Cytotoxicity toward targets loaded with a K(b)-restricted tyrosinase-related protein 2-derived peptide correlated with depigmentation. The data presented strongly support a role for HSP70i in progressive depigmentation in vivo.
C1 [Denman, Cecele J.; Hariharan, Vidhya; Klarquist, Jared; Oyarbide-Valencia, Kepa; Le Poole, I. Caroline] Loyola Univ, Inst Oncol, Dept Pathol, Maywood, IL 60153 USA.
   [McCracken, James; Guevara-Patino, Jose A.] Univ Chicago, Dept Surg, Maywood, IL USA.
RP Le Poole, IC (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol Microbiol & Immunol, Rm 203,2160 S 1st Ave, Maywood, IL 60153 USA.
EM ilepool@lumc.edu
RI Guevara, Jose/AAD-6707-2020
FU NIAMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R03 AR050137, R01 AR054749]
CR Asea Alexzander, 2006, Current Immunology Reviews, V2, P209, DOI 10.2174/157339506778018514
   Barisic-Drusko V, 2004, COLLEGIUM ANTROPOL, V28, P277
   Bendz H, 2007, J BIOL CHEM, V282, P31688, DOI 10.1074/jbc.M704129200
   Bivik C, 2007, CARCINOGENESIS, V28, P537, DOI 10.1093/carcin/bgl152
   Boissy RE, 2004, PIGM CELL RES, V17, P208, DOI 10.1111/j.1600-0749.2004.00130.x
   Das PK, 2001, TRENDS IMMUNOL, V22, P130, DOI 10.1016/S1471-4906(00)01844-5
   Engelhorn ME, 2006, NAT MED, V12, P198, DOI 10.1038/nm1363
   Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804
   Haug M, 2005, EUR J IMMUNOL, V35, P3163, DOI 10.1002/eji.200535050
   HEDSTRAND H, 2006, ARCH DERMATOL RES, V298, P131
   Kroll TM, 2005, J INVEST DERMATOL, V124, P798, DOI 10.1111/j.0022-202X.2005.23653.x
   Lane C, 2004, CANCER RES, V64, P1509, DOI 10.1158/0008-5472.CAN-03-3227
   Lauterbach H, 2006, J IMMUNOL, V176, P4600, DOI 10.4049/jimmunol.176.8.4600
   Le Poole I. Caroline, 2008, V10, P227, DOI 10.1159/000131485
   LEPOOLE IC, 1993, J INVEST DERMATOL, V100, P816, DOI 10.1111/1523-1747.ep12476645
   LEPOOLE IC, 1993, EXP CELL RES, V205, P388, DOI 10.1006/excr.1993.1102
   Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849
   Marnbula SS, 2007, METHODS, V43, P168, DOI 10.1016/j.ymeth.2007.06.009
   Multhoff G, 2006, HANDB EXP PHARM, V172, P279
   Namazi MR, 2007, PIGM CELL RES, V20, P360, DOI 10.1111/j.1600-0749.2007.00408.x
   NORDLUND JJ, 1983, J AM ACAD DERMATOL, V9, P689, DOI 10.1016/S0190-9622(83)70182-9
   Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203
   Okamoto T, 1998, J INVEST DERMATOL, V111, P1034, DOI 10.1046/j.1523-1747.1998.00411.x
   Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982
   Pido-Lopez J, 2007, J IMMUNOL, V178, P1671, DOI 10.4049/jimmunol.178.3.1671
   Sanchez-Perez L, 2006, J IMMUNOL, V177, P4168, DOI 10.4049/jimmunol.177.6.4168
   Spritz RA, 2007, PIGM CELL RES, V20, P271, DOI 10.1111/j.1600-0749.2007.00384.x
   Steitz J, 2000, INT J CANCER, V86, P89, DOI 10.1002/(SICI)1097-0215(20000401)86:1<89::AID-IJC14>3.0.CO;2-I
   Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2
   Trimble C, 2003, VACCINE, V21, P4036, DOI 10.1016/S0264-410X(03)00275-5
NR 30
TC 59
Z9 64
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD AUG
PY 2008
VL 128
IS 8
BP 2041
EP 2048
DI 10.1038/jid.2008.45
PG 8
WC Dermatology
SC Dermatology
GA 331SA
UT WOS:000258031700025
PM 18337834
OA Bronze, Green Accepted
DA 2020-07-08
ER

PT J
AU Manolache, L
   Benea, V
AF Manolache, Liana
   Benea, Vasile
TI Stress in patients with alopecia areata and vitiligo
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Article
DE alopecia areata; case-control study; life events; stress; vitiligo
ID PSYCHIATRIC MORBIDITY; LIFE EVENTS; PREVALENCE; PSORIASIS; PATTERN;
   IMPACT; ONSET; INDIA
AB Objective To study the involvement of stress before the onset/development of alopecia areata and vitiligo.
   Patients and method Forty-five outpatients with alopecia areata and 32 outpatients with vitiligo were enrolled. The design was a case-control study (controls had skin diseases unrelated to stress). Stressful events were evaluated using Holmes and Rahe's social readjustment rating scale.
   Results Mean age was around 30 years in both conditions. More than 65% of cases (both alopecia areata and vitiligo) experienced stressful events compared to 22% of controls. The odds ratio was 7.75 for alopecia areata and 6.81 for vitiligo. There was a significant difference in the mean number of stressful events between alopecia areata patients and controls (P = 0.005), and also a significant difference in the number of stressful events between men (P = 0.05) and women (P = 0.001) across these two groups. In the vitiligo group there was a significant difference in the mean number of stressful events between patients and controls only in women (P = 0.02). A potential stressful situation occurred more often in both patient groups. Alopecia areata patients described family problems in 45.6% of patients (especially women), which was statistically significant when compared to controls (P = 0.0004). Personal problems were reported by 35.7% of alopecia areata patients (P = 0.04 compared to controls). Vitiligo patients mentioned personal problems in 47% of cases (one-third were related to exams) and 31% of cases were related to job/financial problems. Again, this was statistically significant when compared to controls (P = 0.0002).
   Conclusions Stress seems to play an important role in the onset and aggravation of both alopecia areata and vitiligo, mostly with one stressful event before disease onset.
C1 Cetatea Histria Polyclin, Bucharest, Romania.
   Scarlat Longhin Clin Dermatol, Bucharest, Romania.
RP Manolache, L (corresponding author), Aleea Politechn Nr 2,Bl 2,SC 2,Ap 16 Sector 6, Bucharest 060816, Romania.
EM manoliana@b.astral.ro
RI Manolache, Liana/J-6369-2015
OI Manolache, Liana/0000-0003-2357-4229
CR AGARWAL G, 1998, FAM PRACT S1, V15, pS198
   Brajac I, 2003, J DERMATOL, V30, P871, DOI 10.1111/j.1346-8138.2003.tb00341.x
   COLON EA, 1991, COMPR PSYCHIAT, V32, P245, DOI 10.1016/0010-440X(91)90045-E
   CORRIN E, 2000, DERMATOL PSYCHOSO S1, V1, P42
   Elgowieni M, 2003, DERMATOL PSYCHOSOM, V4, P107
   Firooz A, 2004, INT J DERMATOL, V43, P811, DOI 10.1111/j.1365-4632.2004.02059.x
   Gieler U, 2000, DERMATOL PSYCHOSOM, V1, P6
   Gulec AT, 2004, INT J DERMATOL, V43, P352, DOI 10.1111/j.1365-4632.2004.02028.x
   Gupta MA, 1996, J AM ACAD DERMATOL, V34, P1030, DOI 10.1016/S0190-9622(96)90284-4
   Gupta MA, 1997, ACTA DERM-VENEREOL, V77, P296
   HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
   Koo John Y. M., 1994, International Journal of Dermatology, V33, P849, DOI 10.1111/j.1365-4362.1994.tb01018.x
   MANOLACHE L, 2002, JEADV S1, V16, P299
   Manolache L, 2003, DERMATOL PSYCHOSOM, V4, P112
   Mattoo SK, 2002, J EUR ACAD DERMATOL, V16, P573, DOI 10.1046/j.1468-3083.2002.00590.x
   Mattoo SK, 2001, J DERMATOL, V28, P424, DOI 10.1111/j.1346-8138.2001.tb00004.x
   Onunu AN, 2003, INT J DERMATOL, V42, P800, DOI 10.1046/j.1365-4362.2003.01908.x
   Panconesi E, 1996, DERMATOL CLIN, V14, P399, DOI 10.1016/S0733-8635(05)70368-5
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Picardi A, 2003, PSYCHOSOMATICS, V44, P374, DOI 10.1176/appi.psy.44.5.374
   Picardi A, 2003, PSYCHOTHER PSYCHOSOM, V72, P150, DOI 10.1159/000069731
   Poot F, 2004, Rev Med Brux, V25, pA286
   Ruiz-Doblado S, 2003, INT J DERMATOL, V42, P434, DOI 10.1046/j.1365-4362.2003.01340.x
   SAYAR K, 2001, DERMATOL PSYCHOSOM, V2, P12
   Sharma N, 2001, J DERMATOL, V28, P419, DOI 10.1111/j.1346-8138.2001.tb00003.x
   Silvan M, 2004, CUTIS, V73, P163
   Tan E, 2002, INT J DERMATOL, V41, P748, DOI 10.1046/j.1365-4362.2002.01357.x
   VANDERSTEEN P, 1992, ACTA DERM-VENEREOL, V72, P279
   Wygledowska-Kania M, 1996, Psychiatr Pol, V30, P669
NR 29
TC 86
Z9 91
U1 0
U2 7
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0926-9959
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD AUG
PY 2007
VL 21
IS 7
BP 921
EP 928
DI 10.1111/j.1468-3083.2006.02106.x
PG 8
WC Dermatology
SC Dermatology
GA 200UV
UT WOS:000248789200008
PM 17659001
DA 2020-07-08
ER

PT J
AU Picardi, A
   Pasquini, P
   Cattaruzza, MS
   Gaetano, P
   Melchi, CF
   Baliva, G
   Camaioni, D
   Tiago, A
   Abeni, D
   Biondi, M
AF Picardi, A
   Pasquini, P
   Cattaruzza, MS
   Gaetano, P
   Melchi, CF
   Baliva, G
   Camaioni, D
   Tiago, A
   Abeni, D
   Biondi, M
TI Stressful life events, social support, attachment security and
   alexithymia in vitiligo
SO PSYCHOTHERAPY AND PSYCHOSOMATICS
LA English
DT Article
DE stress; life events; attachment; alexithymia; social support; vitiligo;
   skin disease
ID ADULT ATTACHMENT; MULTIDIMENSIONAL SCALE; PSYCHOSOMATIC-MEDICINE;
   PSYCHOLOGICAL DISTRESS; COPING STRATEGIES; CROSS-VALIDATION; RESPONSES;
   STYLES; HEALTH; PERSPECTIVES
AB Background. It has often been suggested that stress might trigger vitiligo. However, only one study supported this hypothesis, and no study explored the role of other personality or social factors. Methods: Out-patients experiencing a recent onset or exacerbation of vitiligo (n = 31) were compared with out-patients with skin conditions in which psychosomatic factors are commonly were regarded as negligible (n = 116). Stressful events during the last 12 months were assessed with Paykel's Interview for Recent Life Events. Attachment style, alexithymia and social support were assessed with the 'Experiences in Close Relationships' questionnaire, the Toronto Alexithymia Scale (TAS-20), and the Multidimensional Scale of Perceived Social Support, respectively. Results: Cases and controls did not differ regarding the total number of events and the number of undesirable, uncontrollable or major events. Three or more uncontrollable events had occurred more frequently among cases than controls. Perceived social support was lower in cases than in controls. Cases scored higher than controls on anxious attachment, tended towards higher scores on avoidant attachment and were classified more often as insecure. Cases scored higher than controls on the TAS-20 and were classified more often as alexithymic or borderline alexithymic. The occurrence of many uncontrollable events, alexithymia and anxious attachment were associated with vitiligo also in multiple logistic regression analysis. Conclusions: These findings suggest that vulnerability to vitiligo is not increased by stressful events, except for many uncontrollable events. Alexithymia, insecure attachment and poor social support appear to increase susceptibility to vitiligo, possibly through deficits in emotion regulation or reduced ability to cope effectively with stress. Copyright (C) 2003 S. Karger AG, Basel.
C1 IRCCS, IDI, Inst Dermatol, Clin Epidemiol Unit, I-00167 Rome, Italy.
   IRCCS, IDI, Inst Dermatol, Dermatol Clin 2, I-00167 Rome, Italy.
   IRCCS, IDI, Inst Dermatol, Dermatol Clin 3, I-00167 Rome, Italy.
   IRCCS, IDI, Inst Dermatol, Dermatol Clin 8, I-00167 Rome, Italy.
   IRCCS, IDI, Inst Dermatol, Dermatol Clin 1, I-00167 Rome, Italy.
   Univ Roma La Sapienza, Dept Publ Hlth, Rome, Italy.
   Univ Roma La Sapienza, Dept Psychiat Sci & Psychol Med, Rome, Italy.
RP Picardi, A (corresponding author), IRCCS, IDI, Inst Dermatol, Clin Epidemiol Unit, Via Monti Creta 104, I-00167 Rome, Italy.
RI Picardi, Angelo/B-2181-2013; Biondi, Massimo/D-3035-2018; Abeni,
   Damiano/AAA-1401-2019
OI Picardi, Angelo/0000-0003-2392-3011; Biondi,
   Massimo/0000-0001-8777-5498; Abeni, Damiano/0000-0002-0167-7617
CR ALLOWAY R, 1987, PSYCHOL MED, V17, P91, DOI 10.1017/S0033291700013015
   Anan RM, 1999, DEV PSYCHOL, V35, P1210, DOI 10.1037/0012-1649.35.5.1210
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1
   BARTHOLOMEW K, 1991, J PERS SOC PSYCHOL, V61, P226, DOI 10.1037/0022-3514.61.2.226
   Bartholomew K, 1997, BRIT J MED PSYCHOL, V70, P249, DOI 10.1111/j.2044-8341.1997.tb01903.x
   BARTHOLOMEW K, 1997, SOURCEBOOK SOCIAL SU
   Biondi M, 1999, PSYCHOTHER PSYCHOSOM, V68, P114, DOI 10.1159/000012323
   BOISSY RE, 1996, CUTANEOUS MED SURG
   BRENNAN KA, 1998, ATTACHMENT THEORY CL
   Bressi C, 1996, J PSYCHOSOM RES, V41, P551, DOI 10.1016/S0022-3999(96)00228-0
   Carpenter EM, 1996, PERS RELATIONSHIP, V3, P351, DOI 10.1111/j.1475-6811.1996.tb00121.x
   COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003
   COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310
   Cohen S, 1996, ANNU REV PSYCHOL, V47, P113, DOI 10.1146/annurev.psych.47.1.113
   Cohen S., 2000, SOCIAL SUPPORT MEASU
   COHEN S, 1985, SOCIAL SUPPORT H LTH
   Cozzarelli C, 1998, J PERS SOC PSYCHOL, V74, P453, DOI 10.1037/0022-3514.74.2.453
   DAHLEM NW, 1991, J CLIN PSYCHOL, V47, P756, DOI 10.1002/1097-4679(199111)47:6<756::AID-JCLP2270470605>3.0.CO;2-L
   Eker D, 2000, SOC PSYCH PSYCH EPID, V35, P228, DOI 10.1007/s001270050232
   Fava GA, 2000, PSYCHOTHER PSYCHOSOM, V69, P184, DOI 10.1159/000012393
   FAVA GA, 1981, VERSIONE ITALIANA SC
   Feeney BC, 1996, J PERS SOC PSYCHOL, V70, P255, DOI 10.1037/0022-3514.70.2.255
   Florian V, 1995, J PSYCHOL, V129, P665, DOI 10.1080/00223980.1995.9914937
   Grassi L, 2000, PSYCHOTHER PSYCHOSOM, V69, P95, DOI 10.1159/000012372
   Gunnar MR, 1996, DEV PSYCHOBIOL, V29, P191, DOI 10.1002/(SICI)1098-2302(199604)29:3<191::AID-DEV1>3.0.CO;2-M
   KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J
   Kent G, 1996, J AM ACAD DERMATOL, V35, P895, DOI 10.1016/S0190-9622(96)90112-7
   KOBLENZER CS, 1983, ARCH DERMATOL, V119, P501, DOI 10.1001/archderm.119.6.501
   Kraemer S, 1995, J PSYCHOSOM RES, V39, P937, DOI 10.1016/0022-3999(95)00511-0
   LAKCY B, 2000, SOCIAL SUPPORT MEASU
   LESSER IM, 1981, PSYCHOSOM MED, V43, P531, DOI 10.1097/00006842-198112000-00009
   Lotti T, 1999, INT J DERMATOL, V38, P673, DOI 10.1046/j.1365-4362.1999.00767.x
   Luminet O, 2001, PSYCHOTHER PSYCHOSOM, V70, P254, DOI 10.1159/000056263
   Lumley MA, 1996, J PSYCHOSOM RES, V41, P519, DOI 10.1016/S0022-3999(96)00227-9
   MARTIN JB, 1985, PSYCHOTHER PSYCHOSOM, V43, P169, DOI 10.1159/000287876
   MARTIN JB, 1986, PSYCHOTHER PSYCHOSOM, V45, P66, DOI 10.1159/000287930
   MIKULINCER M, 1993, J PERS SOC PSYCHOL, V64, P817, DOI 10.1037/0022-3514.64.5.817
   MIKULINCER M, 1998, ATTACHMENT THEORY CL
   Naatanen P, 1999, PSYCHOTHER PSYCHOSOM, V68, P252, DOI 10.1159/000012341
   Nordlund JJ, 1997, DERMATOL CLIN, V15, P69, DOI 10.1016/S0733-8635(05)70416-2
   NORUSIS MJ, 1998, SPSS WINDOWS PROFESS
   Ognibene TC, 1998, J SOC PERS RELAT, V15, P323, DOI 10.1177/0265407598153002
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Paykel ES, 1997, PSYCHOL MED, V27, P301, DOI 10.1017/S0033291796004424
   PAYKEL ES, 1983, J PSYCHOSOM RES, V27, P341, DOI 10.1016/0022-3999(83)90065-X
   Picardi A, 2000, BRIT J DERMATOL, V143, P983, DOI 10.1046/j.1365-2133.2000.03831.x
   Picardi A, 2001, PSYCHOTHER PSYCHOSOM, V70, P118, DOI 10.1159/000056237
   PICARDI A, IN PRESS G ITAL PSIC
   Picardi A., 2000, RIV PSICHIATR, V35, P114
   PORTER JR, 1990, J AM ACAD DERMATOL, V22, P221, DOI 10.1016/0190-9622(90)70028-G
   RAPHAEL KG, 1991, HEALTH PSYCHOL, V10, P62, DOI 10.1037/0278-6133.10.1.62
   REIS H, 2000, SOCIAL SUPPORT MEASU
   Russiello F., 1995, J EUR ACAD DERMATOL, V5, P234, DOI [10.1016/0926-9959(95)00096-1, DOI 10.1016/0926-9959(95)00096-1]
   SALMINEN JK, 1994, J PSYCHOSOM RES, V38, P681, DOI 10.1016/0022-3999(94)90020-5
   Scheidt CE, 1999, J NERV MENT DIS, V187, P47, DOI 10.1097/00005053-199901000-00008
   Sifneos PE, 1996, AM J PSYCHIAT, V153, P137
   Stone LA, 2001, PSYCHOTHER PSYCHOSOM, V70, P92, DOI 10.1159/000056232
   TAYLOR G, 1992, INTERFACES PSYCHOANA
   TAYLOR GJ, 1984, AM J PSYCHIAT, V141, P725
   Troisi A, 2001, J NERV MENT DIS, V189, P311, DOI 10.1097/00005053-200105000-00007
   TURNER RJ, 1995, MEASURING STRESS
   Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488
   Valera EM, 2001, PSYCHOTHER PSYCHOSOM, V70, P239, DOI 10.1159/000056261
   VANMOFFAERT M, 1992, PSYCHOTHER PSYCHOSOM, V58, P125, DOI 10.1159/000288621
   Waters E, 2000, CHILD DEV, V71, P684, DOI 10.1111/1467-8624.00176
   WEINER H, 1982, J AM ACAD PSYCHOAN, V10, P27, DOI 10.1521/jaap.1.1982.10.1.27
   ZIMET GD, 1990, J PERS ASSESS, V55, P610, DOI 10.1207/s15327752jpa5503&4_17
   ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2
NR 69
TC 77
Z9 81
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0033-3190
J9 PSYCHOTHER PSYCHOSOM
JI Psychother. Psychosom.
PD MAY-JUN
PY 2003
VL 72
IS 3
BP 150
EP 158
DI 10.1159/000069731
PG 9
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 678FK
UT WOS:000182854300006
PM 12707482
DA 2020-07-08
ER

PT J
AU Picardi, A
   Abeni, D
AF Picardi, A
   Abeni, D
TI Stressful life events and skin diseases: Disentangling evidence from
   myth
SO PSYCHOTHERAPY AND PSYCHOSOMATICS
LA English
DT Review
DE psychological stress; life change events; skin diseases; psoriasis;
   alopecia areata; atopic dermatitis; urticaria; acne; vitiligo; lichen
   planus
ID ORAL LICHEN-PLANUS; ATOPIC-DERMATITIS; ALOPECIA-AREATA;
   PSYCHIATRIC-DISORDERS; EMOTIONAL-STRESS; PSORIASIS; DERMATOLOGY;
   SYMPTOMS; URTICARIA; NEUROPEPTIDES
AB The possibility of a causal influence of emotional stress, especially of stressful life events, on the course of various skin diseases has long been postulated. Clinical wisdom and experience, as well as many anecdotal observations and uncontrolled case series, support this opinion. We reviewed the available evidence on the role of stressful life events in triggering or exacerbating skin diseases. The role of stressful events in vitiligo, lichen planus, acne, pemphigus and seborrhoeic dermatitis was either controversial or insufficiently explored. The role of stressful events in psoriasis, alopecia areata, atopic dermatitis and urticaria was apparently clearer. However, only a few studies met acceptable methodological standards for stress measurement. Also, few studies considered common potential confounding factors (e.g. age, duration of illness, familial factors), and no study controlled adequately for the influence of other crucial factors (e.g. discontinuation of treatment, seasonal effects). Adding that the large majority of studies were retrospective, it seems wise to conclude that only preliminary evidence has been published so far on the role of stressful life events in bringing on or worsening any dermatological disease. Further research is mandatory, either in the form of prospective studies or, more feasibly, of well-designed case-control studies with adequate statistical power. Future studies should also pay more attention to protective as well as vulnerability factors in stressful events. Further, it would be important to investigate other sources of psychological stress, such as ch ron ic stress and everyday stress. Measuring stress appraisal, although difficult, would also be important. Copyright (C) 2001 S. Karger AG, Basel.
C1 IRCCS, IDI, Inst Dermatol Immacolata, Clin Epidemiol Unit, I-00167 Rome, Italy.
RP Picardi, A (corresponding author), IRCCS, IDI, Inst Dermatol Immacolata, Clin Epidemiol Unit, Via Monti di Creta 104, I-00167 Rome, Italy.
EM angelo.picardi@flashnet.it
RI Picardi, Angelo/B-2181-2013; Abeni, Damiano/AAA-1401-2019
OI Picardi, Angelo/0000-0003-2392-3011; Abeni, Damiano/0000-0002-0167-7617
CR Aktan S, 1998, DERMATOLOGY, V197, P230, DOI 10.1159/000018002
   ALABADIE MS, 1994, BRIT J DERMATOL, V130, P199, DOI 10.1111/j.1365-2133.1994.tb02900.x
   ALKHAWAJAH M, 1991, ANN SAUDI MED, V11, P651, DOI 10.5144/0256-4947.1991.651
   ALLEN CM, 1986, ORAL SURG ORAL MED O, V61, P44, DOI 10.1016/0030-4220(86)90201-X
   ALTMAN J, 1961, ARCH DERMATOL, V84, P179, DOI 10.1001/archderm.1961.01580140005001
   ANDERSON I, 1950, BRIT MED J, V2, P1250, DOI 10.1136/bmj.2.4691.1250
   BALDARO B, 1989, MED PSICOSOMATICA, V34, P271
   Baldaro B, 1989, MED PSICOSOMATICA, V34, P47
   BALDARO B, 1987, MED PSICOSOM, V32, P307
   BAUGHMAN R, 1971, ARCH DERMATOL, V103, P599, DOI 10.1001/archderm.103.6.599
   BEARE JM, 1978, BRIT J DERMATOL, V98, P553, DOI 10.1111/j.1365-2133.1978.tb01941.x
   Bergbrant I M, 1991, Acta Derm Venereol Suppl (Stockh), V167, P1
   Biondi M, 1996, PSYCHOTHER PSYCHOSOM, V65, P229, DOI 10.1159/000289082
   Biondi M, 1999, PSYCHOTHER PSYCHOSOM, V68, P111, DOI 10.1159/000012321
   BOLGERT M, 1955, Ann Dermatol Syphiligr (Paris), V82, P252
   BOYD AS, 1989, J AM ACAD DERMATOL, V21, P985, DOI 10.1016/S0190-9622(89)70287-5
   Braun-Falco O, 1972, Munch Med Wochenschr, V114, P1105
   BRENNER S, 1984, J AM ACAD DERMATOL, V11, P524, DOI 10.1016/S0190-9622(84)80380-1
   Buhk H, 1997, HAUTARZT, V48, P5, DOI 10.1007/s001050050539
   Burkhart NW, 1996, J AM DENT ASSOC, V127, P648, DOI 10.14219/jada.archive.1996.0277
   Capoore HS, 1998, POSTGRAD MED J, V74, P662, DOI 10.1136/pgmj.74.877.662
   CLEARY PJ, 1980, J PSYCHOSOM RES, V24, P199, DOI 10.1016/0022-3999(80)90042-2
   COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003
   Cohen S., 1995, MEASURING STRESS
   Cossidente A, 1982, G Ital Dermatol Venereol, V117, P337
   COTTERILL JA, 1989, BRIT J HOSP MED, V42, P401
   Cremniter D, 1998, ARCH DERMATOL, V134, P1486, DOI 10.1001/archderm.134.11.1486
   Dahan S, 1998, NOUV DERMATOL, V17, P90
   DE GRACIANSKY P, 1952, Ann Dermatol Syphiligr (Paris), V79, P5
   de la Brassinne M, 1986, ACTA PSYCHIAT BELG, V86, P36
   DEWAARDVANDERSPEK FB, 1989, CLIN EXP DERMATOL, V14, P429
   DEWEERT J, 1984, DERMATOLOGICA, V168, P224, DOI 10.1159/000249708
   DUGAS M, 1983, ACTA PAEDOPSYCHIATR, V49, P221
   ENGEL GL, 1980, AM J PSYCHIAT, V137, P535
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   FARBER EM, 1968, ARCH DERMATOL, V98, P248, DOI 10.1001/archderm.98.3.248
   FARBER EM, 1986, J AM ACAD DERMATOL, V14, P305, DOI 10.1016/S0190-9622(86)70034-0
   FARBER EM, 1974, DERMATOLOGICA, V148, P1, DOI 10.1159/000251595
   FAVA GA, 1980, BRIT J MED PSYCHOL, V53, P277, DOI 10.1111/j.2044-8341.1980.tb02551.x
   Fava GA, 2000, PSYCHOTHER PSYCHOSOM, V69, P184, DOI 10.1159/000012393
   Felten D. L., 1990, PSYCHONEUROIMMUNOLOG
   FORNASA CV, 1982, GIORN ITAL DERMAT V, V117, P211
   Fortune DG, 1998, J AM ACAD DERMATOL, V39, P196, DOI 10.1016/S0190-9622(98)70074-X
   Fortune DG, 1997, BRIT J DERMATOL, V137, P755
   GASTON L, 1991, ACTA DERM-VENEREOL, P37
   GASTON L, 1987, J AM ACAD DERMATOL, V17, P82, DOI 10.1016/S0190-9622(87)70176-5
   GIL KM, 1987, J PSYCHOSOM RES, V31, P673, DOI 10.1016/0022-3999(87)90016-X
   GINSBURG IH, 1995, DERMATOL CLIN, V13, P793, DOI 10.1016/S0733-8635(18)30043-3
   GIP L, 1969, ACTA DERM-VENEREOL, V49, P180
   GOULD WM, 1983, J AM ACAD DERMATOL, V9, P73, DOI 10.1016/S0190-9622(83)70109-X
   Green J, 1997, GENITOURIN MED, V73, P253
   Greenhill MH, 1942, ARCH DERMATOL SYPH, V46, P187, DOI 10.1001/archderm.1942.01500140003001
   GRIESEMER RD, 1978, PSYCHIAT ANN, V8, P49
   GUIDANO VF, 1991, SELF PROCESS
   GUPTA MA, 1990, ARCH DERMATOL, V126, P90, DOI 10.1001/archderm.126.1.90
   GUPTA MA, 1994, PSYCHOSOM MED, V56, P36, DOI 10.1097/00006842-199401000-00005
   Gupta MA, 1996, J AM ACAD DERMATOL, V34, P1030, DOI 10.1016/S0190-9622(96)90284-4
   Gupta MA, 1997, ACTA DERM-VENEREOL, V77, P296
   Harrington CI, 1997, BRIT J DERMATOL, V137, P478, DOI 10.1111/j.1365-2133.1997.tb03771.x
   Harvima RJ, 1996, ACTA DERM-VENEREOL, V76, P467
   HAWKINS NG, 1957, AM REV TUBERC PULM, V75, P768
   HELLGREN L, 1964, ACTA DERM-VENEREOL, V44, P191
   HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
   HUGHES JE, 1983, BRIT J PSYCHIAT, V143, P51, DOI 10.1192/bjp.143.1.51
   INVERNIZZI G, 1987, Medical Science Research, V15, P1219
   JOHNSON FYA, 1995, INT J DERMATOL, V34, P244, DOI 10.1111/j.1365-4362.1995.tb01589.x
   KARVONEN J, 1992, ACTA DERM-VENEREOL, V72, P208
   KATUGAMPOLA G, 1990, INT J DERMATOL, V29, P234, DOI 10.1111/j.1365-4362.1990.tb03816.x
   KING RM, 1991, J PSYCHOSOM RES, V35, P697, DOI 10.1016/0022-3999(91)90120-D
   KISSLING S, 1993, HAUTARZT, V44, P569
   KOBLENZER CS, 1983, ARCH DERMATOL, V119, P501, DOI 10.1001/archderm.119.6.501
   KOBLENZER CS, 1986, INT J DERMATOL, V25, P28, DOI 10.1111/j.1365-4362.1986.tb03398.x
   Kodama A, 1999, J ALLERGY CLIN IMMUN, V104, P173, DOI 10.1016/S0091-6749(99)70130-2
   LAMMINTAUSTA K, 1991, INT J DERMATOL, V30, P563
   Liakopoulou M, 1997, J AM ACAD CHILD PSY, V36, P678, DOI 10.1097/00004583-199705000-00019
   LORENZ TH, 1953, J LAB CLIN MED, V41, P11
   LOTTI T, 1995, J AM ACAD DERMATOL, V33, P482, DOI 10.1016/0190-9622(95)91395-5
   Luger TA, 1998, J EUR ACAD DERMATOL, V10, P207, DOI 10.1016/S0926-9959(98)00009-9
   LYKETSOS GC, 1985, PSYCHOTHER PSYCHOSOM, V44, P122, DOI 10.1159/000287903
   MACALPINE I, 1958, BRIT J DERMATOL, V70, P118
   MAHONEY MJ, 1995, COGNITIVE CONSTRUCTI
   MAZZETTI M, 1994, ACTA DERM-VENEREOL, V74, P62
   MEHLMAN RD, 1968, AM J PSYCHIAT, V125, P605, DOI 10.1176/ajp.125.5.605
   MICHAELS.G, 1969, ACTA DERM-VENEREOL, V49, P404
   Mikulincer M, 1998, ATTACHMENT THEORY CL
   Monroe S, 1995, MEASURING STRESS
   MULLER SA, 1963, ARCH DERMATOL, V88, P290, DOI 10.1001/archderm.1963.01590210048007
   NEIMEYER RA, 2000, CONSTRUCTION DISORDE
   NEIMEYER RA, 1992, CASEBOOK CONSTRUCTIV
   Nevitt GJ, 1996, BRIT J DERMATOL, V135, P533, DOI 10.1111/j.1365-2133.1996.tb03826.x
   Niemeier V, 1998, DERMATOLOGY, V196, P108, DOI 10.1159/000017842
   NYFORS A, 1975, BRIT J DERMATOL, V92, P437, DOI 10.1111/j.1365-2133.1975.tb03105.x
   PAGA G, 1992, NEW TRENDS EXP CLIN, V8, P73
   Panconesi E, 1996, DERMATOL CLIN, V14, P399, DOI 10.1016/S0733-8635(05)70368-5
   Papadopoulos L, 1998, CLIN EXP DERMATOL, V23, P243
   Park Byung Soon, 1998, Journal of Dermatology (Tokyo), V25, P97
   PAYKEL ES, 1983, J PSYCHOSOM RES, V27, P341, DOI 10.1016/0022-3999(83)90065-X
   PAYNE RA, 1985, CLIN EXP DERMATOL, V10, P239, DOI 10.1111/j.1365-2230.1985.tb00564.x
   PERINI GI, 1984, PSYCHOTHER PSYCHOSOM, V41, P48, DOI 10.1159/000287786
   PERRY HO, 1965, ARCH DERMATOL, V91, P10, DOI 10.1001/archderm.1965.01600070016002
   Picardi A, 2000, BRIT J DERMATOL, V143, P983, DOI 10.1046/j.1365-2133.2000.03831.x
   POIKOLAINEN K, 1994, BRIT J DERMATOL, V130, P473, DOI 10.1111/j.1365-2133.1994.tb03380.x
   Polenghi M M, 1989, Acta Derm Venereol Suppl (Stockh), V146, P84
   Polenghi M M, 1987, G Ital Dermatol Venereol, V122, P167
   POLENGHI MM, 1994, ACTA DERM-VENEREOL, V74, P65
   RABKIN JG, 1976, SCIENCE, V194, P1013, DOI 10.1126/science.790570
   RAJKA G, 1986, INT J DERMATOL, V25, P301, DOI 10.1111/j.1365-4362.1986.tb02249.x
   RAPHAEL KG, 1991, HEALTH PSYCHOL, V10, P62, DOI 10.1037/0278-6133.10.1.62
   RECHARDT M, 1991, ACTA DERM-VENEREOL, P56
   REES L, 1957, J PSYCHOSOM RES, V2, P172, DOI 10.1016/0022-3999(57)90002-8
   REINHOLD M, 1960, BRIT MED J, V1, P846, DOI 10.1136/bmj.1.5176.846
   ROQUETA FJF, 1996, ACTA DERMOSIFILIOGR, V87, P597
   ROS AM, 1987, J AM ACAD DERMATOL, V17, P752, DOI 10.1016/S0190-9622(87)70258-8
   Russiello F., 1995, J EUR ACAD DERMATOL, V5, P234, DOI [10.1016/0926-9959(95)00096-1, DOI 10.1016/0926-9959(95)00096-1]
   Ryff CD, 2000, PSYCHOTHER PSYCHOSOM, V69, P170, DOI 10.1159/000012390
   SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932
   SCHUDEL P, 1985, Z HAUTKRANKHEITEN, V60, P479
   SEVILLE RH, 1977, BRIT J DERMATOL, V97, P297, DOI 10.1111/j.1365-2133.1977.tb15186.x
   Shalita A., 1980, DERMATOLOGY, V3, P23
   SHUSTER S, 1979, BRIT J DERMATOL, V100, P614, DOI 10.1111/j.1365-2133.1979.tb05591.x
   STEWART JH, 1989, CUTIS, V43, P340
   SULZBERGER MB, 1948, MED CLIN N AM, P669
   SUSSKIND W, 1959, Scott Med J, V4, P503
   TAKAHASHI S, 1996, JPN J PSYCHOSOM MED, V36, P337
   TAMIR A, 1994, DERMATOLOGY, V189, P210, DOI 10.1159/000246837
   TERASHIMA Y, 1989, JPN J PSYCHIAT NEUR, V43, P585
   TESHIMA H, 1982, PSYCHOTHER PSYCHOSOM, V37, P165, DOI 10.1159/000287569
   TOMPKINS JK, 1955, ARCH DERMATOL, V71, P515, DOI 10.1001/archderm.1955.01540280091022
   TURNER RJ, 1995, MEASURING STRESS
   ULLMAN KC, 1977, J ASTHMA RES, V14, P91, DOI 10.3109/02770907709098955
   VANDERSTEEN P, 1992, ACTA DERM-VENEREOL, V72, P279
   VANMOFFAERT M, 1992, PSYCHOTHER PSYCHOSOM, V58, P125, DOI 10.1159/000288621
   WELTMANN G, 1966, HAUTARZT, V17, P7
   WESSELY SC, 1989, BRIT J PSYCHIAT, V155, P686
   Wethington E, 1995, MEASURING STRESS
   WITTKOWER E, 1951, AMA ARCH DERM SYPH, V63, P207, DOI 10.1001/archderm.1951.01570020041005
   Woodruff PWR, 1997, GEN HOSP PSYCHIAT, V19, P29, DOI 10.1016/S0163-8343(97)00155-2
   Wygledowska-Kania M, 1996, Psychiatr Pol, V30, P669
   York J, 1998, PSYCHOL REP, V82, P1044
   ZALKA AD, 1994, ARCH DERMATOL, V130, P390, DOI 10.1001/archderm.130.3.390
   Zorrilla EP, 1996, AM J PSYCHIAT, V153, P626
NR 141
TC 149
Z9 156
U1 2
U2 27
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0033-3190
EI 1423-0348
J9 PSYCHOTHER PSYCHOSOM
JI Psychother. Psychosom.
PD MAY-JUN
PY 2001
VL 70
IS 3
BP 118
EP 136
DI 10.1159/000056237
PG 19
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 430EP
UT WOS:000168561600002
PM 11340413
DA 2020-07-08
ER

EF